<SEC-DOCUMENT>0001193125-16-552147.txt : 20160422
<SEC-HEADER>0001193125-16-552147.hdr.sgml : 20160422
<ACCEPTANCE-DATETIME>20160422165208
ACCESSION NUMBER:		0001193125-16-552147
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20160422
DATE AS OF CHANGE:		20160422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-201581
		FILM NUMBER:		161587131

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d158779d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR> Registration No. 333-201581<BR> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(TO PROSPECTUS DATED APRIL 22,
2016) </B></P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158779g67c03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
supplement relates to the offer and sale of up to $100,000,000 of shares of our common stock from time to time through our sales agent, JonesTrading Institutional Services LLC, which we refer to herein as JonesTrading or the sales agent. These
sales, if any, will be made under an at market issuance sales agreement, dated January&nbsp;6, 2016, between us and JonesTrading, or the Sales Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These shares will be offered at market prices prevailing at the time of sale. Unless we and JonesTrading agree otherwise, we will pay
JonesTrading a commission equal to 1.7% of the sales price of all shares sold through it as our agent. The net proceeds, if any, that we receive from the sales of our common stock will depend on the number of shares actually sold and the offering
price for such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed for trading on The Nasdaq Global Market under the symbol &#147;OMER.&#148; On
April&nbsp;21, 2016, the last reported sale price of our common stock on The Nasdaq Global Market was $13.69&nbsp;per share. Based on the closing price of our common stock on April 21, 2016, the maximum number of shares we could sell under this
prospectus supplement and the accompanying prospectus is 7,304,601. We estimate the offering expenses, other than the sales agent&#146;s commissions, will be approximately $275,000. If we were to sell 7,304,601&nbsp;shares of common stock at the
April 21, 2016 closing sales price, we would receive $100.0 million in gross proceeds, which is approximately $98.0 million in net proceeds. The actual proceeds to us will vary. There is no arrangement for funds to be received in any escrow, trust
or similar arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our common stock under this prospectus supplement, if any, may be made by any method that is deemed to be
an &#147;at the market offering&#148; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. This includes sales made directly on The Nasdaq Global Market or sales made to or through a market maker other than on
an exchange. With our prior written consent, sales may also be made in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law.
JonesTrading will make all sales using commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Global Market, on mutually
agreeable terms between JonesTrading and us. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our common stock involves significant risks. Before buying shares of our common stock, you should carefully consider the risks described under the caption &#147;<A HREF="#supprom158779_5">Risk Factors</A>&#148; beginning on page S-4 of this
prospectus supplement and in the documents incorporated by reference into this prospectus supplement. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158779g23h26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is April 22, 2016. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_1">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_2">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_3">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_4">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_5">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_8">Price Range of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_9">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_13">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom158779_14">Incorporation of Documents by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_2">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_3">About Omeros</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_4">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_5">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_6">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_7">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_8">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_9">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_10">Description of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_11">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_12">Description of Depository Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_13">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_14">Description of Subscription Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_15">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_16">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_17">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom158749_18">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common
stock and updates the information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part is the accompanying prospectus, which provides more general information, some of which does
not apply to this offering. If information included or incorporated by reference in this prospectus supplement is inconsistent with the accompanying prospectus or the information incorporated by reference therein, then this prospectus supplement or
the information incorporated by reference in this prospectus supplement will apply and will supersede the information in the accompanying prospectus and the documents incorporated by reference therein. For a more detailed understanding of our common
stock, you should read both this prospectus supplement and the accompanying prospectus, together with additional information described under the heading &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a shelf registration statement on Form S-3 (File No.&nbsp;333-201581) that we filed with the U.S.
Securities and Exchange Commission, or SEC, on January&nbsp;16, 2015 and amended on March&nbsp;15, 2016. Under the shelf registration process, we may from time to time offer and sell any combination of the securities described in the accompanying
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference in this prospectus supplement, the
accompanying prospectus and any free writing prospectus prepared by us or on our behalf. Neither we nor the sales agent have authorized anyone to provide you with different or additional information. If anyone provides you with different or
additional information, you should not rely on it. Neither we nor the sales agent are making an offer to sell or soliciting an offer to buy our common stock under any circumstance in any jurisdiction where the offer or solicitation is not permitted.
You should assume that the information contained in this prospectus supplement, the accompanying prospectus and any free writing prospectus prepared by us or on our behalf is accurate only as of the date of the respective document in which the
information appears, and that any information in documents that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or any sale
of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus supplement, the accompanying prospectus, and the information incorporated herein and therein by reference includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names
included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, in this prospectus supplement and the accompanying prospectus the terms &#147;Omeros,&#148;
&#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Omeros Corporation, a Washington corporation, and its subsidiaries on a consolidated basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_2"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the information incorporated by reference in this prospectus supplement and the
accompanying prospectus contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act, which are subject to the safe
harbor created by those sections for such statements. Forward- looking statements are based on our management&#146;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical
facts are forward-looking statements. Terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions and variations thereof are intended to identify forward-looking statements, but these terms are not the
exclusive means of identifying such statements. Those statements appear in this prospectus supplement, the accompanying prospectus and the documents incorporated herein and therein by reference, particularly in the sections entitled &#147;Prospectus
Summary&#148; and &#147;Risk Factors,&#148; and include statements regarding the intent, belief or current expectations of us and our management that are subject to known and unknown risks, uncertainties and assumptions. Examples of these statements
include, but are not limited to, statements regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans for sales, marketing and distribution of OMIDRIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (phenylephrine and ketorolac injection) 1%/0.3%; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our product sales and our estimate regarding how long our existing cash, cash equivalents, short-term investments and revenues will be sufficient to fund our anticipated operating expenses,
capital expenditures and interest and principal payments on our outstanding notes under our Loan and Security Agreement with Oxford Finance LLC and East West Bank, or the Loan Agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to raise additional capital through the capital markets, including under the Sales Agreement, or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing
arrangements or asset sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to forecast accurately wholesaler demand as well as our estimates of chargebacks and rebates, distribution fees and estimated product returns; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into acceptable arrangements with potential corporate partners, including with respect to OMIDRIA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the clinical, therapeutic and competitive benefits of OMIDRIA and our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipation that we will rely on contract manufacturers to manufacture OMIDRIA for commercial sale and to manufacture our product candidates and our expectations regarding product supply and manufacturing of
OMIDRIA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations about the commercial competition that OMIDRIA and our product candidates, if commercialized, may face; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectation that the OMIDRIAssure&#153; Reimbursement Services Program will increase patient access to OMIDRIA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding cost impacts resulting from hiring sales representatives from Ventiv Commercial Services, LLC; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of protection that our patents provide and that our pending patent applications will provide, if patents issue from such applications, for our technologies, programs, products and product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the dosing limitations in our OMS824 program may be removed; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to design and successfully complete clinical trials and other studies for our products and product candidates and our plans and expectations regarding our clinical trials, including our clinical trials for
OMS721 and OMS824; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expected course and costs of existing claims, legal proceedings and administrative actions, our involvement in potential claims, legal proceedings and administrative actions, and the potential outcomes and effects
of both existing and potential claims, legal proceedings and administrative actions, as well as regulatory determinations, on our business, prospects, financial condition and results of operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our OMS103 exclusive license agreement including, without limitation, manufacturing and commercialization of OMS103 and the commencement and subsequent continuation of product sales on which
we could receive royalty revenue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expected financial position, performance, revenues, growth, expenses, magnitude of net losses and the availability of resources. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks,
uncertainties and other factors described in this prospectus supplement, the accompanying prospectus and the documents incorporated herein and therein by reference, particularly in the sections entitled &#147;Risk Factors&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Given these risks, uncertainties and other factors, actual results or anticipated developments may not be realized or, even if substantially
realized, may not have the expected consequences to or effects on our company, business or operations. Accordingly, you should not place undue reliance on these forward-looking statements, which represent our estimates and assumptions only as of the
date they are made. You should read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein with the understanding that our actual results in subsequent periods may materially differ
from current expectations. Except as required by law, we assume no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus supplement and the accompanying prospectus. It does not contain
all of the information you should consider before making an investment decision. Before you decide to invest in our securities, you should read the entire prospectus supplement and the accompanying prospectus carefully, including the risk factors
and the financial statements and related notes included or incorporated by reference herein and therein. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for
large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our marketed drug product OMIDRIA is currently being sold in the U.S. for use during cataract surgery or intraocular lens
replacement. OMIDRIA is derived from our proprietary PharmacoSurgery<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;platform, which is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic,
urological and other surgical procedures. Our proprietary PharmacoSurgery platform is based on low-dose combinations of U.S. Food and Drug Administration-approved therapeutic agents delivered directly to the surgical site throughout the duration of
the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We also have five clinical-stage development programs in our pipeline, which include a
diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
in the State of Washington in 1994. Our principal executive offices are located at 201 Elliott Avenue West, Seattle, Washington 98119, and our telephone number is (206)&nbsp;676-5000. Our website address is www.omeros.com. The information on, or
that can be accessed through, our website is not part of this prospectus supplement or the accompanying prospectus. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $100,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>Assuming all $100,000,000 of our common stock is sold in this offering at an assumed offering price of $13.69 per share, which was the last reported sale price of our common stock on The Nasdaq Global Market on April 21, 2016, we would have had
46,423,755&nbsp;shares of common stock outstanding as of March&nbsp;31, 2016. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Manner of offering </P></TD>
<TD>An &#147;at the market offering&#148; of shares of our common stock. The sale of shares of our common stock under this prospectus supplement, if any, may be made directly on The Nasdaq Global Market, or through a market maker other than on an
exchange. With our prior written consent, sales may also be made in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. See
&#147;Plan of Distribution&#148; on page S-9 of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Sales agent </P></TD>
<TD>JonesTrading Institutional Services LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from sales under the Sales Agreement, if any, for general corporate purposes including expenses related to the continued commercialization of OMIDRIA, research and development expenses such as funding clinical
trials, pre-clinical studies, manufacturing development and costs associated with otherwise advancing our drug candidates toward New Drug Application and Biologic License Application submissions. The net offering proceeds may also be used for
working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to our own, and other capital expenditures. See &#147;Use of Proceeds&#148; on <FONT
STYLE="white-space:nowrap">page&nbsp;S-6</FONT> of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; beginning on page S-4 of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market listing </P></TD>
<TD>Our common stock is listed on The Nasdaq Global Market under the symbol &#147;OMER.&#148; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering, as reported above, is based on 39,119,154 shares
outstanding as of March&nbsp;31, 2016, and excludes as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">9,302,348 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $8.40 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,189,575 shares of common stock available for future grants under our 2008 Equity Incentive Plan. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should
consider carefully the risks described below and discussed under the section captioned &#147;Risk Factors&#148; in Part I, Item&nbsp;1A of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, which is incorporated by reference
in this prospectus supplement and the accompanying prospectus in their entirety, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, together with other information in this prospectus supplement, the
accompanying prospectus, and the information and documents incorporated by reference that we have authorized for use in connection with this offering. If any of these risks actually occur, our business, financial condition, results of operations or
cash flows could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price has been and may continue to be volatile, and the value of an investment in our common stock may decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, our stock traded as high as $30.23 per share and as low as $10.48 per share. The trading price
of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to numerous factors, many of which are beyond our control. In addition, the stock market has experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of publicly traded companies. Broad market and industry factors may seriously affect the market price of companies&#146; stock, including ours, regardless
of actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#146;s
securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#146;s attention and resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the price per share of our common stock being offered is expected to be substantially higher than the net tangible book value per share
of our common stock, your interest will be diluted to the extent of the difference between the price per share you pay and the net tangible book value per share of our common stock. See the section entitled &#147;Dilution&#148; below for a more
detailed discussion of the dilution you will incur if you purchase common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have broad discretion as to
the use of proceeds from this offering, and we may not use the proceeds effectively. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in
the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. You will not have the opportunity, as part of your investment
decision, to assess whether these proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the further development of OMIDRIA and our product candidates and cause
the price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect that we may need additional capital in the future; however, such capital may not be available to
us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing
shareholders would experience further dilution. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we expect that we may need additional capital in the future, we cannot
be certain that it will be available to us on acceptable terms when required, or at all. Disruptions in the global equity and credit markets may limit our ability to access capital. To the extent that we raise additional funds by issuing equity
securities, our shareholders would experience dilution, which may be significant and could cause the market price of our common stock to decline significantly. Any debt financing, if available, may restrict our operations similar to the Loan
Agreement, or in other ways. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the commercialization of OMIDRIA or the development or commercialization of
one or more of our product candidates or one or more of our other research and development initiatives. We also could be required to seek collaborators for one or more of our current or future products or product candidates at an earlier stage than
otherwise would be desirable or on terms that are less favorable than otherwise might be available or to relinquish or license on unfavorable terms our rights to technologies or products or product candidates that we otherwise would seek to develop
or commercialize ourselves. We also may have insufficient funds or otherwise be unable to advance our preclinical programs, such as potential new drug targets developed from our GPCR program, to a point where they can generate revenue through
partnerships, collaborations or other arrangements. Any of these events could significantly harm our business and prospects and could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares by holders of outstanding options could cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2016, approximately 11.5&nbsp;million shares of common stock are either subject to outstanding options, or reserved for future
issuance under our employee benefit plans. The shares underlying these securities will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and as granted by us under our employee
benefit plans. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Washington law could make an acquisition of us, which may be beneficial to our shareholders,
difficult and prevent attempts by our shareholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our articles of
incorporation and bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on shareholder actions by less than unanimous written
consent, restrictions on the ability of shareholders to fill board vacancies and the ability of our board of directors to issue preferred stock without shareholder approval. In addition, because we are incorporated in Washington, we are governed by
the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other things, restricts the ability of shareholders owning 10% or more of our outstanding voting stock from merging or combining with us. Although we believe
these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some shareholders. In
addition, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it difficult for shareholders to replace members of our board of directors, which is responsible for
appointing the members of our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never declared or paid dividends on our capital stock, and we do not anticipate paying dividends
in the foreseeable future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business requires significant funding, and we have not generated any material revenue. We
currently plan to invest all available funds and future earnings, if any, in the development and growth of our business. Additionally, under the Loan Agreement we have agreed not to pay any dividends. Therefore, we currently do not anticipate paying
any cash dividends on our common stock in the foreseeable future. As a result, a rise in the market price of our common stock, which is uncertain and unpredictable, will be the sole source of potential gain for shareholders in the foreseeable
future, and an investment in our common stock for dividend income should not be relied upon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds that we receive from sales of our common stock pursuant to this prospectus supplement will depend on the number of shares
actually sold and the offering price for such shares. There can be no assurance that we will be able to sell any shares under, or fully utilize, the Sales Agreement as a source of financing. Based on the closing price of our common stock on
April&nbsp;21, 2016 of $13.69, the maximum number of shares we could sell is 7,304,601. We estimate the offering expenses, other than the sales agent&#146;s commissions, will be approximately $275,000. If we were to sell 7,304,601 shares of common
stock at the April&nbsp;21, 2016 closing price, we would receive $100.0 million in gross proceeds, which is approximately $98.0&nbsp;million in net proceeds. The actual proceeds, if any, to us will vary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from sales under the Sales Agreement, if any, for general corporate purposes including expenses related to
the continued commercialization of OMIDRIA, research and development expenses such as funding clinical trials, pre-clinical studies, manufacturing development and costs associated with otherwise advancing our drug candidates toward New Drug
Application and Biologic License Application submissions. We may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to our own,
and other capital expenditures. Our management will have broad discretion in the application of the net proceeds received from this offering, if any. Pending use of the net proceeds of this offering as described above, we intend to invest any net
proceeds in short-term, investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase our common stock in this offering, your interest will be diluted to the extent of the difference between the price per share
you pay and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book deficit as of December&nbsp;31, 2015 was approximately $(26.2) million, or $(0.69) per share. Net tangible book deficit per
share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December&nbsp;31, 2015. Dilution with respect to net tangible book value per share represents the
difference between the amount per share paid by purchasers of shares of common stock in this public offering and the net tangible book value per share of our common stock immediately after this public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below assumes for illustrative purposes that 7,304,601 shares of our common stock are sold at a price of $13.69, which was the
closing price of our common stock on The Nasdaq Global Market on April&nbsp;21, 2016, for aggregate gross proceeds of $100.0 million. After giving effect to the offering, based on these assumptions and after deducting the sales commission and
estimated offering expenses payable by us, our adjusted net tangible book value as of December&nbsp;31, 2015 would have been approximately $71.8 million, or $1.58 per share. This would represent an immediate increase in the net tangible book value
of $2.27 per share to existing shareholders and immediate dilution in net tangible book value of $13.69 per share to investors purchasing our common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book deficit per share as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors purchasing our common
stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share on December&nbsp;31, 2015, after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing our common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the assumptions reflected in this table, the shares sold in this offering, if any, will be
sold from time to time at various prices. The dilution per share to new investors purchasing our common stock in this offering will depend on the number and price of shares of our common stock that are sole in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering, as reported above, is based on 38,040,891 shares
outstanding as of December&nbsp;31, 2015, and excludes as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,310,235 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $7.97 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">749,250 shares of common stock issuable upon the exercise of outstanding warrants with a weighted- average exercise price of $0.01 per share (which shares were issued in the first quarter of 2016); and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,724,987 shares of common stock available for future grants under our 2008 Equity Incentive Plan (which increased to 3,510,703 shares of common stock on January&nbsp;1, 2016 pursuant to the terms of the 2008 Equity
Incentive Plan). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or warrants outstanding as of December&nbsp;31, 2015 have been or
may be exercised or other shares issued, or to the extent that equity awards granted subsequent to December&nbsp;31, 2015 (of which there have been 1,599,705 stock options granted with a weighted-average exercise price of $10.84) are exercised or
become vested, investors purchasing our common stock in this offering may experience further dilution. We also may choose to raise additional capital due to favorable market conditions or strategic considerations even if we believe that we have
sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_8"></A>PRICE RANGE OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Market under the symbol &#147;OMER.&#148; The following table sets forth the range of high and
low sales prices of our common stock as quoted on The Nasdaq Global Market for the periods indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Year Ended December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2nd Quarter (through April 21, 2016)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1st Quarter </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Year Ending December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4th Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3rd Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2nd Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1st Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Year Ended December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4th Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3rd Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2nd Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1st Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 21, 2016, the closing sale price of our common stock, as reported by Nasdaq was $13.69 per share. As
of March 31, 2016, there were approximately 143 holders of record of our common stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_9"></A>DIVIDEND POLICY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock, and under the Loan Agreement we have agreed not to pay any
dividends. We expect to retain all available funds and future earnings, if any, to fund the development and growth of our business and we do not anticipate paying any cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into the Sales Agreement, under which we may issue and sell shares of our common stock having aggregate gross proceeds of up
to $100,000,000. The actual dollar amount and number of shares of common stock that we sell pursuant to this prospectus supplement will be dependent, among other things, on market conditions and our fundraising requirements. JonesTrading may sell
common stock by any method deemed to be an &#147;at the market offering&#148; as defined in Rule 415 under the Securities Act, including directly on The Nasdaq Global Market or in sales made to or through a market maker other than on an exchange.
With our prior written consent, sales may also be made in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time that we wish to issue and sell common stock under the Sales Agreement, we will provide JonesTrading with a placement notice
describing the number of shares to be issued, the time period during which sales are requested to be made, any limitation on the number of shares that may be sold in any one day and any minimum price below which sales may not be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These shares will be offered at market prices prevailing at the time of sale. Unless we and JonesTrading agree otherwise, we will pay
JonesTrading a commission equal to 1.7% of the sales price of all shares sold through it as our agent. Because there is no minimum offering amount required as a condition to closing this offering, the actual total public offering amount, commissions
and proceeds to us, if any, are not determinable at this time. The expenses of the offering, not including the compensation payable to JonesTrading under the Sales Agreement, are estimated to be approximately $275,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Sales Agreement, JonesTrading will use commercially reasonable efforts consistent with its normal trading and sales practices to
sell any shares subject to a placement notice. In connection with the sale of common stock on our behalf, JonesTrading may, and will with respect to sales effected in an &#147;at the market offering,&#148; be deemed to be an underwriter within the
meaning of the Securities Act, and the compensation of JonesTrading may be deemed to be underwriting commissions or discounts. We have agreed to indemnify JonesTrading against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for shares of our common stock will occur on the third business day following the date on which any sales are made, or on some
other date that is agreed upon by us and JonesTrading in connection with a particular transaction, in return for payment of the net proceeds to us. Settlement will occur through the facilities of The Depository Trust Company or by such other means
as we and JonesTrading may agree upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of our common stock pursuant to the Sales Agreement will terminate upon the earlier
of (i)&nbsp;the issuance and sale of all of the shares of our common stock subject to the Sales Agreement, or (ii)&nbsp;the termination of the Sales Agreement as permitted therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">JonesTrading and its affiliates may in the future provide various investment banking and other financial services for us and our affiliates,
for which services they may in the future receive customary fees. To the extent required by Regulation M, JonesTrading will not engage in any market making activities involving our common stock while the offering under this prospectus supplement is
ongoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common stock offered hereby and certain legal matters in connection with this offering will be passed upon by Marcia S.
Kelbon, Vice President, Patent and General Counsel and Secretary of Omeros, and Mark A. Metcalf, Associate General Counsel, Corporate Finance and Governance, and Assistant Secretary of Omeros. As of April 21, 2016, Ms.&nbsp;Kelbon held 163,597
shares of our common stock and Ms.&nbsp;Kelbon and Mr.&nbsp;Metcalf held options under our equity incentive plans to purchase up to 641,673 and 62,700 additional shares of our common stock, respectively, and were eligible to receive additional
equity awards under such plans. Certain other legal matters in connection with this offering will be passed upon by Covington&nbsp;&amp; Burling LLP, Washington, D.C. Duane Morris LLP, New York, New York, is counsel to the sales agent in connection
with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Omeros Corporation appearing in Omeros Corporation&#146;s Annual Report (Form&nbsp;10-K) for the year
ended December&nbsp;31, 2015, and the effectiveness of Omeros Corporation&#146;s internal control over financial reporting as of December&nbsp;31, 2015, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as
set forth in their reports thereon (which contain an explanatory paragraph describing conditions that raise substantial doubt about the company&#146;s ability to continue as a going concern as described in Note 1 to the consolidated financial
statements) included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at www.sec.gov. You may also read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the Public Reference Room. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the
SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act can also be accessed free of charge by linking directly from our website at www.omeros.com under the &#147;Investor&#151;Financial Information&#151;SEC Filings&#148; caption to the
SEC&#146;s Edgar Database. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement under the Securities Act relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration
statement. You can obtain a copy of the registration statement at prescribed rates from the SEC at the address listed above. The registration statement and the documents referred to below under &#147;Incorporation by Reference&#148; are also
available on our Internet website, www.omeros.com. We have not incorporated by reference into this prospectus supplement the information on, or that can be accessed through, our website, and you should not consider it to be a part of this prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom158779_14"></A>INCORPORATION OF DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement and the accompanying prospectus, and information that we file later with the SEC will automatically
update and supersede this information. The following documents that we have previously filed with the SEC (File No.&nbsp;001-34475) are incorporated by reference herein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, filed with the SEC on March&nbsp;15, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed with the SEC on January&nbsp;6, 2016 and&nbsp;January&nbsp;19, 2016 (excluding all information furnished in such reports under Item&nbsp;2.02, Item&nbsp;7.01 or Item&nbsp;9.01).
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All reports and other documents that we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act prior to the termination of this offering, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and the accompanying prospectus and deemed to
be part of this prospectus supplement and the accompanying prospectus from the time of the filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus supplement and the accompanying prospectus as further supplemented may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this prospectus supplement or the
accompanying prospectus. You should rely only on the information incorporated by reference or provided in this prospectus supplement and accompanying prospectus. We have not authorized anyone else to provide you with different information. You
should not assume that the information in this prospectus supplement and the accompanying prospectus is accurate as of any date other than the date of this prospectus supplement, the date of the accompanying prospectus or the date of the documents
incorporated by reference in this prospectus supplement and the accompanying prospectus, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide without charge to
each person, including any beneficial owner, to whom this prospectus supplement and accompanying prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus supplement
and accompanying prospectus, but not delivered with the prospectus supplement and accompanying prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus
supplement or accompanying prospectus incorporates. You should direct written requests to: Omeros Corporation, Attn: Legal Department, 201 Elliott Avenue West, Seattle, Washington 98119, or you may call us at (206)&nbsp;676-5000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158779g67c03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Subscription
Rights </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may offer and sell up to $100,000,000 of the securities described in this prospectus separately or together in any combination, in one or more classes or series, in amounts, at prices and on terms that we will determine at the time of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be used to sell securities unless accompanied by a prospectus supplement, which will describe the
method and specific terms of the offering, including the amount, price and terms of the applicable offered securities. You should carefully read this prospectus, the information incorporated by reference in this prospectus, the prospectus
supplement, including any information incorporated by reference in such prospectus supplement, and any free writing prospectus before you purchase any of the securities offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These securities may be offered and sold in the same offering or in separate offerings, to or through underwriters, dealers or agents or
directly to purchasers. The names of any underwriters, dealers or agents involved in the sale of our securities, their compensation and any over-allotment options held by them will be described in the applicable prospectus supplement. See &#147;Plan
of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;OMER.&#148; On April&nbsp;21, 2016,
the closing price of our common stock was $13.69 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves significant risks. Before buying our securities, you should carefully consider the risks described under the caption &#147;<A HREF="#rom149726_6">Risk Factors</A>&#148; beginning on page 3 of this prospectus, in the documents
incorporated by reference into this prospectus, and in the applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&nbsp;April 22, 2016. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_2">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_3">About Omeros</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_4">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_5">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_6">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_7">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_8">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_9">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_10">Description of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_11">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_12">Description of Depositary Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_13">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_14">Description of Subscription Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_15">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_16">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_17">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom149726_18">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-3 that we filed with the United States Securities and Exchange Commission, or
SEC, using a &#147;shelf&#148; registration process. Under this shelf process, we may, from time to time, offer or sell any combination of the securities described in this prospectus in one or more offerings up to a total amount of $100,000,000.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus only provides you with a general description of the securities that we may offer. Each time we sell securities pursuant
to this prospectus, we will describe in a prospectus supplement, which will be delivered with this prospectus, specific information about the offering and the terms of the particular securities offered. The prospectus supplement may also add, update
or change the information contained in this prospectus. Before purchasing any securities, you should carefully read both this prospectus and the accompanying prospectus supplement and any free writing prospectus prepared by or on behalf of us,
together with the additional information described under &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not
contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. Those exhibits may be filed with the
registration statement or may be incorporated by reference to earlier SEC filings listed in the registration statement or in subsequent filings that we may make under the Securities Exchange Act of 1934, or Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference in this prospectus, the accompanying prospectus supplement
or any free writing prospectus that we have prepared which relates to a particular offering. We have not authorized anyone else to provide you with different or additional information. If anyone provides you with different or additional information,
you should not rely on it. We are not making an offer to sell or soliciting an offer to buy these securities under any circumstance in any jurisdiction where the offer or solicitation is not permitted. You should assume that the information
contained in this prospectus, any prospectus supplement or any free writing prospectus that we have prepared is accurate only as of the date of the respective document in which the information appears, and that any information in documents that we
have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of a security. Our business, financial
condition, results of operations and prospects may have changed since those dates. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any prospectus supplement and the
information incorporated herein and therein by reference includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus
supplement or the accompanying prospectus are the property of their respective owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, in this
prospectus supplement and the accompanying prospectus the terms &#147;company,&#148; &#147;Omeros,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Omeros Corporation, a Washington corporation, and its subsidiaries on a
consolidated basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_2"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, or the Securities Act, and Section&nbsp;21E of the Exchange Act, which are subject to the safe harbor created by those sections for such
statements. Forward-looking statements are based on our management&#146;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical fact are forward-looking statements. Terms
such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions and variations thereof are intended to identify forward-looking statements, but these terms are not the exclusive means of identifying such
statements. Those statements appear in this prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein by reference, particularly in the sections entitled &#147;Prospectus Summary&#148; and &#147;Risk
Factors,&#148; and include statements regarding the intent, belief or current expectations of us and our management that are subject to known and unknown risks, uncertainties and assumptions. Examples of forward-looking statements include, but are
not limited to, statements regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans for sales, marketing and distribution of OMIDRIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (phenylephrine and ketorolac injection) 1%/0.3%; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our product sales and our estimate regarding how long our existing cash, cash equivalents, short-term investments and revenues will be sufficient to fund our anticipated operating expenses,
capital expenditures and interest and principal payments on our outstanding notes under our Loan and Security Agreement with Oxford Finance LLC and East West Bank; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to raise additional capital through the capital markets, including under our at-the-market equity facility with JonesTrading Institutional Services LLC or through one or more corporate partnerships, equity
offerings, debt financings, collaborations, licensing arrangements or asset sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to forecast accurately wholesaler demand as well as our estimates of chargebacks and rebates, distribution fees and estimated product returns; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into acceptable arrangements with potential corporate partners, including with respect to OMIDRIA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the clinical, therapeutic and competitive benefits of OMIDRIA and our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipation that we will rely on contract manufacturers to manufacture OMIDRIA for commercial sale and to manufacture our product candidates and our expectations regarding product supply and manufacturing of
OMIDRIA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations about the commercial competition that OMIDRIA and our product candidates, if commercialized, may face; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectation that the OMIDRIAssure&#153; Reimbursement Services Program will increase patient access to OMIDRIA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding cost impacts resulting from hiring sales representatives from Ventiv Commercial Services, LLC; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of protection that our patents provide and that our pending patent applications will provide, if patents issue from such applications, for our technologies, programs, products and product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the dosing limitations in our OMS824 program may be removed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to design and successfully complete clinical trials and other studies for our products and product candidates and our plans and expectations regarding our clinical trials, including our clinical trials for
OMS721 and OMS824; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expected course and costs of existing claims, legal proceedings and administrative actions, our involvement in potential claims, legal proceedings and administrative actions, and the potential outcomes and effects
of both existing and potential claims, legal proceedings and administrative actions, as well as regulatory determinations, on our business, prospects, financial condition and results of operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our OMS103 exclusive license agreement including, without limitation, manufacturing and commercialization of OMS103 and the commencement and subsequent continuation of product sales on which
we could receive royalty revenue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expected financial position, performance, revenues, growth, expenses, magnitude of net losses and the availability of resources. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks,
uncertainties and other factors described in our filings with the SEC. Given these risks, uncertainties and other factors, actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the
expected consequences to or effects on our company, business or operations. Accordingly, you should not place undue reliance on these forward-looking statements, which represent our estimates and assumptions only as of the date they are made. The
events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by law, we assume no obligation
to update or revise any forward-looking statements contained in this prospectus, the accompanying prospectus supplement or any information incorporated by reference herein or therein, whether as a result of any new information, future events or
otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_3"></A>ABOUT OMEROS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for
large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Our marketed drug product OMIDRIA is currently being sold in the U.S. for use during cataract surgery or intraocular lens
replacement. OMIDRIA is derived from our proprietary PharmacoSurgery<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform, which is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological
and other surgical procedures. Our proprietary PharmacoSurgery platform is based on low-dose combinations of U.S. Food and Drug Administration-approved therapeutic agents delivered directly to the surgical site throughout the duration of the
procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We also have five clinical-stage development programs in our pipeline, which include a
diverse group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Washington in 1994. Our principal executive offices are located at 201 Elliott Avenue West, Seattle,
Washington 98119, and our telephone number is (206)&nbsp;676-5000. Our website address is www.omeros.com. The information on, or that can be accessed through, our website is not part of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_4"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at www.sec.gov. You may also read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the Public Reference Room. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the
SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act can also be accessed free of charge by linking directly from our website at www.omeros.com under &#147;Investor &#151; Financial Information &#151; SEC Filings.&#148; These filings will
be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed
with the SEC a registration statement under the Securities Act relating to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This
prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement, at prescribed rates, from the SEC at the address listed above. The registration statement and the
documents referred to below under &#147;Incorporation by Reference&#148; are also available on our Internet website, www.omeros.com. We have not incorporated by reference into this prospectus the information on, or that can be accessed through, our
website, and you should not consider it to be a part of this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_5"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. The
following documents that we have previously filed with the SEC (File No.&nbsp;001-34475) are incorporated by reference herein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, filed with the SEC on March&nbsp;15, 2016; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed with the SEC on January&nbsp;6, 2016 and January&nbsp;19, 2016 (excluding all information furnished in such reports under Item&nbsp;2.02, Item&nbsp;7.01 or Item&nbsp;9.01).
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All reports and other documents that we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act prior to the completion of the sales of the securities offered hereby but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this
prospectus from the date of the filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, as supplemented, may contain information that
updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this prospectus. You should rely only on the information incorporated by reference or provided in this prospectus, the accompanying
prospectus supplement or any free writing prospectus that we have prepared that relates to a particular offering. We have not authorized anyone else to provide you with different or additional information. You should not assume that the information
in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral
request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the
documents that this prospectus incorporates. You should direct written requests to: Omeros Corporation, Attn: Legal Department, 201 Elliott Avenue West, Seattle, Washington 98119, or you may call us at (206)&nbsp;676-5000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will
contain a discussion of the risks applicable to an investment in our securities. Before deciding whether to invest in our securities, you should consider carefully the risks described under the heading &#147;Risk Factors&#148; in the applicable
prospectus supplement and in any of our filings with the SEC that are incorporated by reference therein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_7"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the amount of our fixed charges has exceeded our earnings. The following table sets forth our deficiency of earnings available to
cover fixed charges for each year in the five-year period ended December&nbsp;31, 2015. This information should be read in conjunction with the consolidated financial statements and accompanying notes incorporated by reference into this prospectus.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficiency of earnings available to cover fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deficiency of earnings available to cover fixed charges has been computed on a consolidated basis.
&#147;Earnings&#148; consist of loss from continuing operations before income taxes, plus fixed charges and amortization of capitalized interest. Fixed charges consist of interest expensed and capitalized, amortization of premiums, discounts and
capitalized expenses related to debt and an estimate of the interest component of rent expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we
have no shares of preferred stock outstanding and, consequently, our ratio of combined fixed charges and preference dividends to earnings is the same as our deficiency of earnings available to cover fixed charges as disclosed above. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the prospectus supplement, we intend to use the net proceeds from the sale of securities offered under this
prospectus for general corporate purposes including expenses related to the continued commercialization of OMIDRIA, research and development expenses such as funding clinical trials, pre-clinical studies, manufacturing development and costs
associated with otherwise advancing our drug candidates toward New Drug Application and Biologic License Application submissions. We may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in
businesses, products or technologies that are complementary to our own, and other capital expenditures. We will set forth in the prospectus supplement our intended use for the net proceeds received from the sale of any securities. Pending the use of
such proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_9"></A>DESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, common stock, par value $0.01 per
share, as set forth in the applicable prospectus supplement. The following summary of our common stock does not purport to be complete and is subject to, and is qualified in its entirety by reference to, our Amended and Restated Articles of
Incorporation, or Articles of Incorporation, Amended and Restated Bylaws, or Bylaws, and applicable provisions of the Washington Business Corporation Act, or WBCA. Therefore, you should carefully consider the actual provisions of our Articles of
Incorporation and Bylaws as well as relevant portions of the WBCA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized and Outstanding Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of (i)&nbsp;150,000,000 shares of common stock, par value $0.01 per share, and (ii)&nbsp;20,000,000
shares of preferred stock, par value $0.01 per share. As of March 31, 2016, 39,119,154&nbsp;shares of common stock were outstanding and no shares of preferred stock were outstanding. All outstanding shares of common stock are fully paid and
nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive
ratably such dividends as may be declared by the board of directors out of funds legally available therefor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights and Cumulative Voting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote per share on all matters to be voted on by the shareholders. Our Articles of
Incorporation provide that shareholders are not entitled to cumulate votes in the election of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preemptive Rights; Redemption or Sinking Fund
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions
applicable to our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we liquidate, dissolve or wind up, holders of our common stock are entitled to share ratably in all assets remaining after payment of
liabilities and the liquidation preferences of any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing; Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;OMER.&#148; The transfer agent and registrar for our common stock
is Computershare Inc. Its address is P.O. Box 43006, Providence, Rhode Island 02940-3006 and its telephone number is 1-866-282-4938. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover
Effects of Washington Law and our Articles of Incorporation and Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Washington law, our Articles of
Incorporation and our Bylaws contain provisions that may delay, defer or discourage another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate
takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquiror outweigh the disadvantages of
discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Washington Anti-Takeover
Statute </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chapter 23B.19 of the Washington Business Corporation Act, with limited exceptions, prohibits a &#147;target corporation&#148;
from engaging in specified &#147;significant business transactions&#148; for a period of five years after the share acquisition by an &#147;acquiring person&#148;, unless (a)&nbsp;the significant business transaction or the acquiring person&#146;s
purchase of shares was approved by a majority of the members of the target corporation&#146;s board of directors prior to the acquiring person&#146;s share acquisition or (b)&nbsp;the significant business transaction was both approved by the
majority of the members of the target corporation&#146;s board and authorized at a shareholder meeting by at least two-thirds of the outstanding voting shares (excluding the acquiring person&#146;s shares or shares over which the acquiring person
has voting control) at or subsequent to the acquiring person&#146;s share acquisition. An &#147;acquiring person&#148; is defined as a person or group of persons that beneficially owns 10% or more of the voting securities of the target corporation.
&#147;Significant business transactions&#148; include, among other transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mergers, share exchanges or consolidations with, dispositions of assets to, or issuances of stock to or redemptions of stock from, the acquiring person; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of 5% or more of the employees of the target corporation employed in Washington over a five-year period as a result of the acquiring person&#146;s acquisition of 10% or more of the shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allowing the acquiring person to receive any disproportionate benefit as a shareholder; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">liquidating or dissolving the target corporation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the five-year period,
&#147;significant business transactions&#148; are permitted, as long as they comply with the &#147;fair price&#148; provisions of the statute or are approved by a majority of the outstanding shares other than those of which the acquiring person has
beneficial ownership. A corporation may not &#147;opt out&#148; of this statute. This statute could prohibit or delay the accomplishment of mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Bylaws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Incorporation and Bylaws provide that shareholders can amend or repeal our Bylaws only upon the affirmative vote of the holders
of our voting stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed below, our board of directors has the ability to issue preferred stock with voting or other rights or preferences that could
impede the success of any attempt to effect a change of control. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limits on Ability of Shareholders to Act by Written Consent or Call a Special Meeting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Washington law limits the ability of shareholders of public companies from acting by written consent by requiring unanimous written consent for
a shareholder action to be effective. This limit on the ability of our shareholders to act by less than unanimous written consent may lengthen the amount of time required to take shareholder actions. As a result, a holder controlling a majority of
our capital stock who is unable to obtain unanimous written consent from all of our shareholders would not be able to amend our Bylaws or remove directors without holding a shareholders meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our Articles of Incorporation provide that, unless otherwise required by law,
special meetings of the shareholders may be called only by the chairman of the board, the chief executive officer, the president, or the board of directors acting pursuant to a resolution adopted by a majority of the board members. A shareholder may
not call a special meeting, which may delay the ability of our shareholders to force consideration of a proposal or for holders controlling a majority of our capital stock to take any action, including the removal of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Shareholder Nominations and Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws establish advance notice procedures with respect to shareholder proposals and the nomination of candidates for election as
directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. The Bylaws do not give the board of directors the power to approve or disapprove shareholder nominations of candidates
or proposals regarding business to be conducted at a special or annual meeting of the shareholders. However, our Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These
provisions may also discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise attempting to obtain control of the company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Board Vacancies Filled Only by Directors Then in Office </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only our board of directors may determine the number of directors on our board and fix such number by resolution from time to time. Our
Articles of Incorporation provide that vacancies and newly created seats on our board of directors may only be filled by the majority vote of the remaining members of our board of directors. The inability of our shareholders to determine the number
of directors or to fill vacancies or newly created seats on our board of directors makes it more difficult to change the composition of our board of directors, but these provisions may promote a continuity of existing management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Directors May be Removed Only for Cause </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors may be removed only for cause by the affirmative vote of the holders of our voting stock at a meeting of shareholders called for
such purpose. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Board Classification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, with one class being
elected each year by our shareholders. This system of electing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for shareholders
to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Cumulative Voting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Incorporation provide that shareholders are not entitled to cumulate votes in the election of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_10"></A>DESCRIPTION OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, preferred stock, par value $0.01 per
share, as set forth in the applicable prospectus supplement. The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, our Articles of Incorporation, Bylaws and applicable provisions
of the WBCA. Therefore, you should carefully consider the actual provisions of our Articles of Incorporation and Bylaws as well as relevant portions of the WBCA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our Articles
of Incorporation, our board of directors is authorized, from time to time and without further shareholder action, to issue of up to 20,000,000 shares of preferred stock in one or more series, and to fix the designations, powers, preferences and
rights, and the qualifications, limitations or restrictions applicable to the preferred stock. As of the date of this prospectus, no shares of preferred stock were outstanding and our board of directors has made no provision for the issuance of any
series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights, preferences, privileges and restrictions of the preferred stock of each series will be fixed by
the Articles of Amendment to the Articles of Incorporation relating to that series and will be described in the applicable prospectus supplement. Our board of directors has the discretion to fix the number of shares of any such series and the
designation thereof, and to fix and amend the powers, preferences and rights, and the limitations or restrictions granted to or imposed upon any wholly unissued series of preferred stock, including the voting rights, dividend rights, dividend rate,
conversion rights, rights and terms of redemption (including sinking fund provisions), redemption prices and liquidation preferences of any such series. Our board of directors has authority to decrease the number of shares of any series of preferred
stock that is outstanding, but not below the number of shares of any such series then outstanding. In addition, any such reduction is subject to the powers, preferences and rights, and the qualifications, limitations and restrictions thereof stated
in the Articles of Incorporation or the board resolution originally fixing the number of shares of such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of preferred
stock will affect, and may adversely affect, the rights of holders of common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until our board of directors
determines the specific rights, preferences and privileges attached to that series of preferred stock. The effects of issuing preferred stock could include one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restricting dividends on the common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diluting the voting power of the common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairing the liquidation rights of the common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying or preventing changes in control or management of our company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable
prospectus supplement will specify the terms of the series of preferred stock being offered, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of preferred stock being offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation of the series of preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the per share purchase price of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate or method of determining the dividend rate, if any, including whether the dividend rate is fixed or variable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates on which dividends will accrue and the dividend payment dates; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends will be cumulative or non-cumulative and, if cumulative, the dates from which dividends will accrue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price and the terms and conditions for redemption, if any, including redemption at our option or at the option of the holders, the time period for redemption, and any accumulated dividends or premiums;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the liquidation preference, if any, and any accumulated dividends upon the liquidation, dissolution or winding up of our affairs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sinking fund or similar provision, and, if so, the terms and provisions relating to the purpose and operation of the fund; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, for conversion or exchange of preferred stock for any other class or classes of our securities, including the price or the rate of conversion or exchange and the method, if any, of
adjustment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the voting rights of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any exchange on which the preferred stock will be listed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any or all other preferences and relative, participating, optional or other special rights, privileges or qualifications, limitations or restrictions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the material United States federal income tax consequences relating to the purchase and ownership of the series of preferred stock that is described in the prospectus supplement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no present plans to issue any shares of preferred stock nor are any shares of our preferred stock presently outstanding. Preferred
stock will be fully paid and nonassessable upon issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rank </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, the preferred stock will, with respect to distribution rights and rights
upon liquidation, dissolution or winding up of the company, rank (i)&nbsp;senior to our common stock and to any series of preferred stock which specifically provides that it will rank junior to the preferred stock being offered, (ii)&nbsp;junior to
any series of preferred stock which specifically provides that it will rank senior to the preferred stock being offered and (iii)&nbsp;on parity with any other series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of preferred stock will affect, and may adversely affect, the rights of holders of common stock. It is not possible to state the
actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until our board of directors determines the specific rights attached to that preferred stock. The effects of issuing preferred stock could
include one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restricting dividends on the common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diluting the voting power of the common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairing the liquidation rights of the common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying or preventing changes in control or management of our company. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of preferred stock will have the dividend rights set forth in the applicable prospectus supplement. Dividends on any series of
preferred stock, if cumulative, will be cumulative from and after the date set forth in the applicable prospectus supplement. Any restriction on the repurchase or redemption of shares of preferred stock while dividends on such shares are in arrears
will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will appoint a transfer agent and registrar for the preferred stock that will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Anti-Takeover Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to
&#147;Description of Common Stock &#151; Anti-Takeover Effects of Washington Law and our Articles of Incorporation and Bylaws&#148; for a discussion of provisions of the WBCA and our Articles of Incorporation and Bylaws that may have the effect of
delaying, deferring or preventing a change of control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_11"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, debt securities, including
debentures, notes, bonds and other evidences of indebtedness as set forth in the applicable prospectus supplement. The debt securities may be either secured or unsecured and will either be senior debt securities or subordinated debt securities. The
debt securities will be issued under one or more separate indentures between us and a trustee to be specified in an accompanying prospectus supplement. Senior debt securities will be issued under a senior indenture and subordinated debt securities
will be issued under a subordinated indenture. Together, the senior indenture and the subordinated indenture are called indentures in this description. This prospectus, together with the applicable prospectus supplement, will describe the terms of a
particular series of debt securities that we may offer from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of the material provisions of the
indentures and the debt securities does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the provisions of the applicable indenture and certificates evidencing the applicable debt securities. Therefore,
you should carefully consider the applicable indenture and the certificate evidencing the applicable debt security that is filed as an exhibit to the registration statement that includes this prospectus. Other specific terms of the applicable
indenture and debt securities will be described in the applicable prospectus supplement. If any particular terms of the indenture or debt securities described in a prospectus supplement differ from any of the terms described below, then the terms
described below will be deemed to have been superseded by that prospectus supplement. In this description of the debt securities, the words &#147;Omeros Corporation,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer only to Omeros
Corporation and not to our subsidiary, unless we otherwise expressly state or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate
principal amount for the debt securities of any series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not limited as to the amount of debt securities that we may issue under
the indentures. Unless otherwise provided in a prospectus supplement, a series of debt securities may be reopened to issue additional debt securities of such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular series of debt securities will set forth the material terms of the debt securities being
offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the debt securities and whether they are senior debt securities or subordinated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the person who shall be entitled to receive interest, if other than the record holder on the record date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date or dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates, if any, which may be fixed or variable, at which the debt securities will bear interest, or the method of determining such rate or rates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date from which interest will accrue, the interest payment dates and the regular record dates, or the method for calculating the dates and rates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the place or places where payments of principal and interest may be made; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any mandatory or optional redemption provisions or sinking fund provisions and any applicable redemption or purchase prices associated with these provisions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if issued other than in denominations of $1,000 or any multiple of $1,000, the denominations in which the debt securities shall be issuable; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the method for determining how the principal, premium, if any, or interest will be calculated by reference to an index or formula; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than U.S. currency, the currency or currency units in which principal, premium, if any, or interest will be payable, whether we or a holder may elect payment to be made in a different currency and the
designation of the original currency determination agent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the portion of the principal amount that will be payable upon acceleration of maturity, if other than the entire principal amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the principal amount payable at stated maturity will not be determinable as of any date prior to stated maturity, the amount or method for determining the amount which will be deemed to be the principal amount;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, whether the debt securities will be subject to the defeasance provisions described below under &#147;Satisfaction and Discharge; Defeasance&#148; or such other defeasance provisions specified in the
applicable prospectus supplement for the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any conversion or exchange provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities will be issuable in the form of a global security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any subordination provisions applicable to the subordinated debt securities if different from those described below under &#147;Subordinated Debt Securities&#148;; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any paying agents, authenticating agents, security registrars or other agents for the debt securities, if other than the trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions relating to any security provided for the debt securities, including any provisions regarding the circumstances under which collateral may be released or substituted; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any deletions of, or changes or additions to, the events of default, acceleration provisions or covenants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions relating to guaranties for the securities and any circumstances under which there may be additional obligors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms of such debt securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any
of the debt securities in a foreign currency or currencies, or if the principal of or premium, if any, or interest on any series of debt securities is payable in a foreign currency or currencies, we will include in the applicable prospectus
supplement information on the restrictions, elections, material federal income tax considerations, specific terms and other information with respect to that issue of debt securities and the foreign currency or currencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the prospectus supplement, the debt securities will be registered debt securities. Debt securities may be sold
at a substantial discount below their stated principal amount, bearing no interest or interest at a rate which at the time of issuance is below market rates. The U.S. federal income tax considerations applicable to debt securities sold at a discount
will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange and Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may be transferred or exchanged at the office of the security registrar or at the office of any transfer agent designated by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not impose a service charge for any transfer or exchange, but we may require holders to pay any tax or other governmental
charges associated with any transfer or exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any partial redemption of debt securities of any series, we will not be required
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of or exchange any debt security of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption and ending at the close of
business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt security of that series selected for redemption, in whole or in part, except the unredeemed portion being redeemed in part. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, we will appoint the trustee as the security registrar. Any transfer agent, in addition to the security registrar initially
designated by us, will be named in the prospectus supplement. We may designate additional transfer agents or change transfer agents or change the office of the transfer agent. However, we will be required to maintain a transfer agent in each place
of payment for the debt securities of each series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any debt securities being offered are convertible into or exchangeable for common stock or other securities of the company, the relevant
prospectus supplement will set forth the terms of conversion or exchange. Those terms will include whether conversion or exchange is mandatory, at the option of the holder or at our option, and the number of shares of common stock or other
securities, or the method of determining the number of shares of common stock or other securities, to be received by the holder upon conversion or exchange. These provisions may allow or require the number of shares of our common stock or other
securities to be received by the holders of such series of debt securities to be adjusted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of any series may be represented, in whole or in part, by one or more global securities. Each global security will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be registered in the name of a depositary, or its nominee, that we will identify in a prospectus supplement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be deposited with the depositary or nominee or custodian; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bear any required legends. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No global security may be exchanged in whole or in part for debt
securities registered in the name of any person other than the depositary or any nominee unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary has notified us that it is unwilling or unable to continue as depositary or has ceased to be qualified to act as depositary; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an event of default has occurred and is continuing with respect to the debt securities of the applicable series; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other circumstance described in a prospectus supplement has occurred permitting or requiring the issuance of any such security. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as the depositary, or its nominee, is the registered owner of a global security, the depositary or nominee will be considered the sole
owner and holder of the debt securities represented by the global security for all purposes under the indentures. Except in the above limited circumstances, owners of beneficial interests in a global security will not be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entitled to have the debt securities registered in their names; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entitled to physical delivery of certificated debt securities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considered to be holders of those debt securities under the indenture. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments on a global security will be made to the depositary or its nominee as the holder of the
global security. Some jurisdictions have laws that require that certain purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the ability to transfer beneficial interests in a global security.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Institutions that have accounts with the depositary or its nominee are referred to as &#147;participants.&#148; Ownership of beneficial
interests in a global security will be limited to participants and to persons that may hold beneficial interests through participants. The depositary will credit, on its book-entry registration and transfer system, the respective principal amounts
of debt securities represented by the global security to the accounts of its participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a global
security will be shown on and effected through records maintained by the depositary, with respect to participants&#146; interests, or any participant, with respect to interests of persons held by participants on their behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments, transfers and exchanges relating to beneficial interests in a global security will be subject to policies and procedures of the
depositary. The depositary policies and procedures may change from time to time. Neither any trustee nor we will have any responsibility or liability for the depositary&#146;s or any participant&#146;s records with respect to beneficial interests in
a global security. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in a prospectus supplement, the provisions described in this paragraph will apply to the debt securities. Payment of
interest on a debt security on any interest payment date will be made to the person in whose name the debt security is registered at the close of business on the regular record date. Payment on debt securities of a particular series will be payable
at the office of a paying agent or paying agents designated by us. However, at our option, we may pay interest by mailing a check to the record holder. The trustee will be designated as our initial paying agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also name any other paying agents in a prospectus supplement. We may designate additional paying agents, change paying agents or change
the office of any paying agent. However, we will be required to maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All moneys paid by us to a paying agent for payment on any debt security that remain unclaimed for a period ending the earlier of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">10 business days prior to the date the money would be turned over to the applicable state; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at the end of two years after such payment was due, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">will be repaid to us thereafter. The holder may look only
to us for such payment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will not
contain any provisions that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction, whether or not such transaction results in a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in
a prospectus supplement with respect to a particular series of debt securities, the debt securities will not contain any financial or restrictive covenants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, we may not consolidate with or
merge into any other person, in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to, any entity, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successor entity, if any, is a corporation, limited liability company, partnership, trust or other business entity existing under the laws of the United States, any State within the United States or the District of
Columbia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successor entity assumes our obligations on the debt securities and under the applicable indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain other conditions specified in the indenture are met. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement with respect to a particular series of debt securities, the following will be events of
default for any series of debt securities under the indentures: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">we fail to pay any interest on any debt security of that series when it becomes due and we subsequently fail to pay such interest for 30 days; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">we fail to pay principal of or any premium on any debt security of that series when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">we fail to deposit any sinking fund payment when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">we fail to perform any other covenant in the applicable indenture and such failure continues for 90 days after we are given the notice required in the indentures; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">certain events including our bankruptcy, insolvency or reorganization. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional or
different events of default applicable to a series of debt securities may be described in a prospectus supplement. An event of default of one series of debt securities is not necessarily an event of default for any other series of debt securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee may withhold notice to the holders of any default, except defaults in the payment of principal, premium, if any, interest,
any sinking fund installment on, or with respect to any conversion right of, the debt securities of such series. However, the trustee must consider it to be in the interest of the holders of the debt securities of such series to withhold this
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement, if an event of default, other than an event of default described in
clause (5)&nbsp;above, shall occur and be continuing with respect to any series of debt securities, either the trustee or the holders of at least 25% in aggregate principal amount of the outstanding securities of that series may declare the
principal amount and premium, if any, of the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case
together with accrued and unpaid interest, if any, thereon, to be due and payable immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default described in clause
(5)&nbsp;above shall occur, the principal amount and premium, if any, of all the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable
prospectus supplement, in each case together with accrued and unpaid interest, if any, thereon, will automatically become immediately due and payable without any declaration or other action on the part of the trustee or any holder. Any payment by us
on the subordinated debt securities following any such acceleration will be subject to the subordination provisions described below under &#147;Subordinated Debt Securities.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After acceleration, the holders of a majority in aggregate principal amount of the outstanding
securities of that series may, under certain circumstances, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal, or other specified amounts or interest, have been cured or waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the duty to act with the required care during an event of default, the trustee will not be obligated to exercise any of its rights
or powers at the request of the holders unless the holders shall have offered to the trustee reasonable indemnity. Generally, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series will have the
right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of debt securities of any series will not have any right to institute any proceeding under the indentures, or for the appointment of
a receiver or a trustee, or for any other remedy under the indentures, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the holder has previously given to the trustee written notice of a continuing event of default with respect to the debt securities of that series; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least a majority in aggregate principal amount of the outstanding debt securities of that series have made a written request and have offered reasonable indemnity to the trustee to institute the
proceeding; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the trustee has failed to institute the proceeding and has not received direction inconsistent with the original request from the holders of a majority in aggregate principal amount of the outstanding debt securities of
that series within 60 days after the original request. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may, however, sue to enforce the payment of principal,
premium or interest on any debt security on or after the due date or to enforce the right, if any, to convert any debt security (if the debt security is convertible) without following the procedures listed in clauses (1)&nbsp;through (3)&nbsp;above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish the trustee an annual statement by our officers as to whether or not we are in default in the performance of the
conditions and covenants under the indenture and, if so, specifying all known defaults. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement, we and the applicable trustee may make modifications and amendments to an indenture
with the consent of the holders of a majority in aggregate principal amount of the outstanding securities of each series affected by the modification or amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also make modifications and amendments to the indentures for the benefit of holders without their consent, for certain purposes
including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing for our successor to assume the covenants under the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adding covenants or events of default; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making certain changes to facilitate the issuance of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing the securities, including provisions relating to the release or substitution of collateral; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing for guaranties of, or additional obligors on, the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing for a successor trustee or additional trustees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">curing any ambiguities or inconsistencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permitting or facilitating the defeasance and discharge of the securities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other changes specified in the indenture. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, neither we nor the trustee may make any modification or amendment without the consent of
the holder of each outstanding security of that series affected by the modification or amendment if such modification or amendment would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the stated maturity of any debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal, premium, if any, or interest on any debt security or any amount payable upon redemption or repurchase, whether at our option or the option of any holder, or reduce the amount of any sinking fund
payments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal of an original issue discount security or any other debt security payable on acceleration of maturity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the place of payment or the currency in which any debt security is payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impair the right to enforce any payment after the stated maturity or redemption date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if subordinated debt securities, modify the subordination provisions in a materially adverse manner to the holders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adversely affect the right to convert any debt security if the debt security is a convertible debt security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the provisions in the indenture that relate to modifying or amending the indenture. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Satisfaction
and Discharge; Defeasance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be discharged from our obligations on the debt securities, subject to limited exceptions, of any
series that have matured or will mature or be redeemed within one year if we deposit enough money with the trustee to pay all of the principal, interest and any premium due to the stated maturity date or redemption date of the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture contains a provision that permits us to elect either or both of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may elect to be discharged from all of our obligations, subject to limited exceptions, with respect to any series of debt securities then outstanding. If we make this election, the holders of the debt securities of
the series will not be entitled to the benefits of the indenture, except for the rights of holders to receive payments on debt securities or the registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated
debt securities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may elect to be released from our obligations under some or all of any financial or restrictive covenants applicable to the series of debt securities to which the election relates and from the consequences of an
event of default resulting from a breach of those covenants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To make either of the above elections, we must irrevocably
deposit in trust with the trustee enough money to pay in full the principal, interest and premium on the debt securities. This amount may be made in cash and/or U.S. government obligations or, in the case of debt securities denominated in a currency
other than U.S. dollars, cash in the currency in which such series of securities is denominated and/or foreign government obligations. As a condition to either of the above elections, for debt securities denominated in U.S. dollars we must deliver
to the trustee an opinion of counsel that the holders of the debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Foreign government obligations&#148; means, with respect to debt securities of any series that are denominated in a currency other than
United States dollars: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">direct obligations of the government that issued or caused to be issued the currency in which such securities are denominated and for the payment of
which obligations its full faith and credit is pledged, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
or, with respect to debt securities of any series which are denominated in euros, direct obligations of certain members of the European Union for the payment of which obligations the full faith
and credit of such members is pledged, which in each case are not callable or redeemable at the option of the issuer thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obligations of a person controlled or supervised by or acting as an agency or instrumentality of a government described in the bullet above, the timely payment of which is unconditionally guaranteed as a full faith and
credit obligation by such government, which are not callable or redeemable at the option of the issuer thereof; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any depository receipt issued by a bank as custodian with respect to any obligation specified in the first two bullet points and held by such bank for the account of the holder of such deposit any receipt, or with
respect to any such obligation which is so specified and held. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notices to holders will be given by mail to the addresses of the holders in the security register. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
debt securities will be governed by, and construed under, the laws of the State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal Liability of Directors, Officers, Employees
and Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No incorporator, shareholder, employee, agent, officer, director or subsidiary of ours will have any liability for
any obligations of ours, or because of the creation of any indebtedness under the debt securities, the indentures or supplemental indentures. The indentures provide that all such liability is expressly waived and released as a condition of, and as a
consideration for, the execution of such indentures and the issuance of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures limit the right of the trustee, should it become our creditor, to obtain payment of claims or secure its claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee is permitted to engage in certain other transactions with us. However, if the trustee acquires any conflicting interest, and there
is a default under the debt securities of any series for which it is trustee, the trustee must eliminate the conflict or resign. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying prospectus supplement will specify the trustee for the particular series of debt securities to be issued under the indentures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordinated Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following provisions will be applicable with respect to each series of subordinated debt securities, unless otherwise stated in the prospectus supplement relating to that series of subordinated debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indebtedness evidenced by the subordinated debt securities of any series is subordinated, to the extent provided in the subordinated
indenture and the applicable prospectus supplement, to the prior payment in full, of all senior debt, including any senior debt securities, in cash or other payment satisfactory to the holders of senior debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any distribution of our assets upon any dissolution, winding up, liquidation or
reorganization, whether voluntary or involuntary, marshalling of assets, assignment for the benefit of creditors, or in bankruptcy, insolvency, receivership or other similar proceedings, payments on the subordinated debt securities will be
subordinated in right of payment to the prior payment in full in cash or other payment satisfactory to holders of senior debt of all senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any acceleration of the subordinated debt securities of any series because of an event of default with respect to the
subordinated debt securities of that series, holders of any senior debt would be entitled to payment in full in cash or other payment satisfactory to holders of senior debt of all senior debt before the holders of subordinated debt securities are
entitled to receive any payment or distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the subordinated debt securities will be structurally subordinated to all
indebtedness and other liabilities of our subsidiaries, including trade payables and lease obligations. This occurs because our right to receive any assets of our subsidiaries upon their liquidation or reorganization, and your right to participate
in those assets, will be effectively subordinated to the claims of that subsidiary&#146;s creditors, including trade creditors, except to the extent that we are recognized as a creditor of such subsidiary. If we are recognized as a creditor of that
subsidiary, our claims would still be subordinate to any security interest in the assets of the subsidiary and any indebtedness of the subsidiary senior to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to promptly notify holders of senior debt or their representatives under the subordinated indenture if payment of the
subordinated debt securities is accelerated because of an event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the subordinated indenture, we may also not make
payment on the subordinated debt securities if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a default in our obligations to pay principal, premium, if any, interest or other amounts on our senior debt occurs and the default continues beyond any applicable grace period, which we refer to as a payment default;
or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a nonpayment default occurs and is continuing with respect to designated senior debt that permits holders of designated senior debt to accelerate its maturity, and the trustee receives a payment blockage notice from us
or some other person permitted to give the notice under the subordinated indenture, which we refer to as a non-payment default. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may and shall resume payments on the subordinated debt securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in case of a payment default, when the default is cured or waived or ceases to exist; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in case of a nonpayment default, the earlier of when the default is cured or waived or ceases to exist or 179 days after the receipt of the payment blockage notice. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No new payment blockage period may start on the basis of a nonpayment default unless at least 365 days have elapsed from the initial
effectiveness of the immediately prior payment blockage notice. No nonpayment default that existed or was continuing on the date of delivery of any payment blockage notice to the trustee shall be the basis for a subsequent payment blockage notice.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these subordination provisions, in the event of our bankruptcy, dissolution or reorganization, holders of senior debt may
receive more, ratably, and holders of the subordinated debt securities may receive less, ratably, than our other creditors. The subordination provisions will not prevent the occurrence of any event of default under the subordinated indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subordination provisions will not apply to payments from money or government obligations held in trust by the trustee for the payment of
principal, interest and premium, if any, on subordinated debt securities pursuant to the provisions described under &#147;Satisfaction and Discharge; Defeasance,&#148; if the subordination provisions were not violated at the time the money or
government obligations were deposited into trust. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the trustee or any holder receives any payment that should not have been made to them in
contravention of subordination provisions before all senior debt is paid in full in cash or other payment satisfactory to holders of senior debt, then such payment will be held in trust for the holders of senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Senior debt securities will constitute senior debt under the subordinated indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional or different subordination provisions may be described in a prospectus supplement relating to a particular series of debt
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Designated senior debt</I><I>&#148;</I> means our obligations under any particular senior debt in which the instrument creating or
evidencing the same or the assumption or guarantee thereof, or related agreements or documents to which we are a party, expressly provides that such indebtedness shall be designated senior debt for purposes of the subordinated indenture. The
instrument, agreement or other document evidencing any designated senior debt may place limitations and conditions on the right of such senior debt to exercise the rights of designated senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Indebtedness</I><I>&#148;</I> means the following, whether absolute or contingent, secured or unsecured, due or to become due,
outstanding on the date of the indenture for such series of securities or thereafter created, incurred or assumed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our indebtedness evidenced by a credit or loan agreement, note, bond, debenture or other written obligation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our obligations for money borrowed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our obligations evidenced by a note or similar instrument given in connection with the acquisition of any businesses, properties or assets of any kind, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our obligations: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as lessee under leases required to be capitalized on the balance sheet of the lessee under generally accepted accounting principles, or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as lessee under other leases for facilities, capital equipment or related assets, whether or not capitalized, entered into or leased for financing purposes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our obligations under interest rate and currency swaps, caps, floors, collars, hedge agreements, forward contracts or similar agreements or arrangements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our obligations with respect to letters of credit, bankers&#146; acceptances and similar facilities, including reimbursement obligations with respect to the foregoing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our obligations issued or assumed as the deferred purchase price of property or services, but excluding trade accounts payable and accrued liabilities arising in the ordinary course of business;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all obligations of the type referred to in the above clauses of another person and all dividends of another person, the payment of which, in either case, we have assumed or guaranteed, for which we are responsible or
liable, directly or indirectly, jointly or severally, as obligor, guarantor or otherwise, or which are secured by a lien on our property; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">renewals, extensions, modifications, replacements, restatements and refundings of, or any indebtedness or obligation issued in exchange for, any such indebtedness or obligation described in the above clauses of this
definition. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Senior debt</I><I>&#148;</I> means the principal of, premium, if any, and interest,
including all interest accruing subsequent to the commencement of any bankruptcy or similar proceeding, whether or not a claim for post-petition interest is allowable as a claim in any such proceeding, on, and all fees and other amounts payable in
connection with, our indebtedness. Senior debt will not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any debt or obligation if its terms or the terms of the instrument under which or pursuant to which it is issued expressly provide it shall not be senior in right of payment to the subordinated debt securities or
expressly provide that such indebtedness is on the same basis or &#147;junior&#148; to the subordinated debt securities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">debt to any of our subsidiaries. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Subsidiary&#148;</I> means an entity more than 50%
of the outstanding voting stock of which is owned, directly or indirectly, by us or by one or more of our other subsidiaries or by a combination of us and our other subsidiaries. For purposes of this definition, &#147;voting stock&#148; means stock
or other similar interests to us which ordinarily has or have voting power for the election of directors, or persons performing similar functions, whether at all times or only so long as no senior class of stock or other interests has or have such
voting power by reason of any contingency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_12"></A>DESCRIPTION OF DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may elect to offer fractional interests in shares of preferred stock, in which case we will issue to the public receipts for depositary
shares and each of these depositary shares will represent a fraction of a share of the applicable series of preferred stock, as set forth in the applicable prospectus supplement. The following summary of the terms of the depositary shares does not
purport to be complete and is subject to, and is qualified in its entirety by reference to, the terms of the depositary shares and preferred stock, as well as the form of the deposit agreement, our Articles of Incorporation and the Articles of
Amendment relating to the applicable series of preferred stock that are, or will be, filed with the SEC. Therefore, you should carefully consider the actual provisions of these documents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each owner of a depositary share
will be entitled, in proportion to the applicable fractional interest in shares of preferred stock underlying that depositary share, to all rights and preferences of the preferred stock underlying that depositary share. These rights may include
dividend, voting, redemption and liquidation rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of preferred stock underlying the depositary shares will be deposited
with a bank or trust company selected by us to act as depositary, under a deposit agreement between us, the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for
the depositary shares. The name and address of the principal executive office of the depositary will be included in the prospectus supplement relating to the issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary shares will be evidenced by depositary receipts issued pursuant to the depositary agreement. Holders of depositary receipts
agree to be bound by the deposit agreement, which requires holders to take certain actions such as filing proof of residence and paying certain charges. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary will distribute cash dividends or other cash distributions, if any, received in respect of the series of preferred stock underlying the depositary shares to the record holders of depositary receipts in proportion to the number of
depositary shares owned by those holders on the relevant record date. The relevant record date for depositary shares will be the same date as the record date for the preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a distribution other than in cash, the depositary will distribute property received by it to the record holders of depositary
receipts that are entitled to receive the distribution, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary, with our approval, may adopt another method for the distribution, including
selling the property and distributing the net proceeds to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of our voluntary or involuntary
liquidation, dissolution or winding up, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a series
of preferred stock underlying the depositary shares is subject to redemption, the depositary shares will be redeemed from the proceeds received by the depositary resulting from the redemption, in whole or in part, of the preferred stock held by the
depositary. Whenever we redeem any preferred stock held by the depositary, the depositary will redeem, as of the same redemption date, the number of depositary shares representing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preferred stock so redeemed. The depositary will mail the notice of redemption to the record holders of the depositary receipts promptly upon receiving the notice from us and no fewer than 20 nor
more than 60 days, unless otherwise provided in the applicable prospectus supplement, prior to the date fixed for redemption of the preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the date fixed for redemption, the depositary shares called for redemption will no longer be outstanding. When the depositary shares are
no longer outstanding, all rights of the holders will end, except the right to receive money, securities or other property payable upon redemption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any
meeting at which the holders of preferred stock are entitled to vote, the depositary will mail the information contained in the notice of meeting to the record holders of the depositary receipts underlying the preferred stock. Each record holder of
those depositary receipts on the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the amount of preferred stock underlying that holder&#146;s depositary shares. The record date for the
depositary will be the same date as the record date for the preferred stock. The depositary will try, as far as practicable, to vote the preferred stock underlying the depositary shares in accordance with these instructions. We will agree to take
all action that may be deemed necessary by the depositary in order to enable the depositary to vote the preferred stock in accordance with these instructions. The depositary will not vote the preferred stock to the extent that it does not receive
specific instructions from the holders of depositary receipts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Owners of depositary shares will be entitled to receive upon surrender of depositary receipts at the principal office of the depositary and
payment of any unpaid amount due to the depositary, the number of whole shares of preferred stock underlying their depositary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partial shares of preferred stock will not be issued. Holders of preferred stock will not be entitled to deposit the shares under the deposit
agreement or to receive depositary receipts evidencing depositary shares for the preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of the Deposit Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement
between the depositary and us. However, any amendment that materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the amendment has been approved by at least a majority of
the outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all outstanding depositary shares have been redeemed; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been made to all the holders of depositary shares. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all
transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangement. We will also pay charges of the depositary in connection with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initial deposit of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initial issuance of the depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any redemption of the preferred stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all withdrawals of preferred stock by owners of depositary shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of depositary receipts will pay transfer, income and other taxes and governmental charges
and other specified charges as provided in the deposit agreement for their accounts. If these charges have not been paid, the depositary may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to transfer depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withhold dividends and distributions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell the depositary shares evidenced by the depositary receipt. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Miscellaneous </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will forward to the holders of depositary receipts all reports and communications we deliver to the depositary that we are
required to furnish to the holders of the preferred stock. In addition, the depositary will make available for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to
time deem advisable, any reports and communications we deliver to the depositary as the holder of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the
depositary will be liable if either we or the depositary are prevented or delayed by law or any circumstance beyond the control of either the depositary or us in performing our respective obligations under the deposit agreement. Our obligations and
the depositary&#146;s obligations will be limited to the performance in good faith of our or the depositary&#146;s respective duties under the deposit agreement. Neither we nor the depositary will be obligated to prosecute or defend any legal
proceeding in respect of any depositary shares or preferred stock unless satisfactory indemnity is furnished. The depositary and we may rely on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">written advice of counsel or accountants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information provided by holders of depositary receipts or other persons believed in good faith to be competent to give such information; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">documents believed to be genuine and to have been signed or presented by the proper party or parties. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and Removal of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may resign at any time by delivering a notice to us. We may remove the depositary at any time. Any such resignation or removal
will take effect upon the appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within 60 days after delivery of the notice for resignation or removal. The successor depositary must
be a bank and trust company having its principal office in the United States of America and having a combined capital and surplus of at least $50,000,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_13"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock, debt securities or any combination thereof. Warrants may be issued
independently or together with common stock, preferred stock or debt securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement, the terms of which will be
described in the applicable prospectus supplement. The following summary of the terms of the warrants does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the terms of the warrants as well as the form
of warrant agreement and the terms of the applicable underlying securities. Therefore, you should carefully consider the actual provisions of these documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase such shares and the price at which such number of shares may be purchased upon such exercise;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred
stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants, which may be payable in cash, securities or other property; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date(s) on which the right to exercise the warrants will commence and the date(s) on which the right will expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">United States federal income tax consequences applicable to the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provision for changes to or adjustments in the exercise price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any anti-dilution or other adjustment provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any mandatory or optional call provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date on and after which the warrants and the common stock, preferred stock or debt securities underlying the warrants will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information with respect to book entry procedures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the identity of the warrant agent; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange, exercise and settlement of the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vote, consent or receive dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receive notice as shareholders with respect to any meeting of shareholders for the election of our directors or any other matter; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exercise any rights as shareholders of Omeros Corporation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt warrant certificates will be
exchangeable for new debt warrant certificates of different denominations. Debt warrants may be exercised at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement. Prior to the exercise of their
debt warrants, holders of debt warrants will not have any of the rights of holders of the debt securities purchasable upon exercise and will not be entitled to payment of principal or premium, if any, or interest on the debt securities purchasable
upon exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_14"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue subscription rights to purchase shares of our common stock or preferred stock. These subscription rights may be issued
independently or together with any other security offered hereby and may or may not be transferable by the shareholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a
standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any offering of subscription rights will include specific terms relating to the offering, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price, if any, for the subscription rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise price payable for each share of common stock or preferred stock upon the exercise of the subscription rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of subscription rights to be offered to each shareholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and terms of the shares of common stock or preferred stock which may be purchased per each subscription right; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the subscription rights are transferable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the subscription rights, including the procedures and limitations relating to the exchange and exercise of the subscription rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the subscription rights will commence and expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities or an over-allotment privilege to the extent the securities are fully subscribed; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the material terms of any standby underwriting or purchase arrangement that we may enter into in connection with the offering of subscription rights. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preceding summary of the terms of the subscription rights does not purport to be complete and is subject to, and is qualified in its
entirety by reference to, the terms of the subscription rights being offered, as well as any applicable subscription rights certificate and the terms of the securities to which the subscription rights relate. Therefore, you should carefully consider
the actual provisions of the subscription right, and subscription agreement and the applicable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_15"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more of the other securities described in this prospectus or any prospectus supplement in any
combination. Each unit will be issued so that the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit. The units may be issued under unit agreements to be entered into between us
and a unit agent, which may provide that the securities included in the unit may not be held or transferred separately, at any time or times before a specified date or upon the occurrence of a specified event or occurrence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances the securities comprising the units may be held or transferred separately;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the terms of any unit agreement governing the units; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the provisions for the payment, settlement, transfer or exchange of the units; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of material federal income tax considerations, if applicable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the units if issued as a separate security will be issued in fully registered or global form. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preceding summary of the terms of the units does not purport to be complete and is subject to, and is qualified in its entirety by
reference to, the terms of the units being offered, as well as any applicable unit agreement and the terms of the applicable classes of securities comprising the unit. Therefore, you should carefully consider the actual provisions of the unit, any
unit agreement and the applicable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_16"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities offered under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions,
block trades or a combination of these methods or through underwriters, dealers or agents or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions at: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fixed price or prices, which may be changed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prices related to the prevailing market price; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time that we sell securities pursuant to this prospectus, we will
provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of the offering of such securities, including the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the names of any underwriters, dealers or agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any managing underwriter or underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the net proceeds from the sale of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any underwriting discounts, concessions, commissions or agency fees and other items constituting underwriters&#146;, dealers&#146; or agents&#146; compensation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delayed delivery arrangements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimated offering expenses. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant to the underwriters options to purchase additional
securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts, as applicable, set forth in the prospectus supplement. The terms of any over-allotment option will be set forth in the
prospectus supplement for those securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in at-the-market offerings into an existing trading market in accordance with
Rule 415(a)(4) under the Securities Act. Any at-the-market offering will be through an underwriter or underwriters acting as principal or agent for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue to our existing security holders, through a dividend or similar distribution, subscription rights to purchase shares of our
common stock or preferred stock, which may or may not be transferable. In any distribution of subscription rights to our existing security holders, if all of the underlying securities are not subscribed for, we may then sell the unsubscribed
securities directly to third parties or may engage the services of one or more underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities to third parties. The applicable prospectus supplement will describe
the specific terms of any offering of our common stock or preferred stock through the issuance of subscription rights, including, if applicable, the material terms of any standby underwriting or purchase arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale Through Underwriters or Dealers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase agreements with us. The underwriters
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may resell the securities from time to time in one or more transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions in any of our
other securities (described in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more managing
underwriters or directly by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters
will be obligated to purchase all the offered securities if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers. The
prospectus supplement will include the names of the underwriters and the terms of the transaction, including any underwriting discounts or commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dealers are used in the sale of securities offered through this prospectus, we will sell the securities to them as principals. They may
then resell those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the dealers and the terms of the transaction, including any discounts or commissions
received. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Direct Sales and Sales Through Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities offered through this prospectus directly. In this case, no underwriters, dealers or agents would be involved. Such
securities may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities and will describe any commissions payable to the agent. Unless otherwise
indicated in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the
Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delayed
Delivery Contracts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement indicates, we may authorize underwriters, dealers or agents to solicit offers from
certain types of institutions to purchase securities at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future. The contracts would be subject only to
those conditions described in the prospectus supplement. The applicable prospectus supplement will describe the commission payable for solicitation of those contracts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Making, Stabilization and Other Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, all preferred stock, debt securities, depositary shares, warrants, subscription
rights and units will be new issues of securities with no established trading market. Unless indicated in the applicable prospectus supplement, we do not expect to list the offered securities on a securities exchange, except for our common stock,
which is listed on The Nasdaq Global Market. Any underwriters that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time without notice. Therefore, we cannot assure you that
the securities will have a liquid trading market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may also engage in stabilizing transactions, syndicate covering
transactions and penalty bids in accordance with Rule 104 of Regulation M under the Exchange Act. Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of preventing or retarding a decline in
the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions. Penalty bids permit the underwriters to
reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of
raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of the securities in the open market may be higher than it would otherwise be in the absence
of these transactions. The underwriters may, if they commence these transactions, discontinue them at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Derivative Transactions and Hedging
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the underwriters or other agents may engage in derivative transactions involving the securities. These derivatives may consist of
short sale transactions and other hedging activities. The underwriters or agents may acquire a long or short position in the securities, hold or resell securities acquired and purchase options or futures on the securities and other derivative
instruments with returns linked to or related to changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security lending or repurchase agreements with the underwriters or agents. The
underwriters or agents may effect the derivative transactions through sales of the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions by others. The underwriters or agents may
also use the securities purchased or borrowed from us or others (or, in the case of derivatives, securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close out any related open
borrowings of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Auctions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities
directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of electronic bidding or ordering systems for the pricing and allocation of such securities, you will want to pay
particular attention to the description of that system, which we will provide in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such electronic system may
allow bidders to directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which such
securities are sold. These bidding or ordering systems may present to each bidder, on a so-called &#147;real-time&#148; basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on
the bids submitted, and whether a bidder&#146;s individual bids would be accepted, prorated or rejected. For example, in the case of debt security, the clearing spread could be indicated as a number of &#147;basis points&#148; above an index
treasury note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or
other factors. The final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet or other electronic bidding process or auction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific terms
of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters,
dealers and agents may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under the Securities Act. Our underwriters, dealers and agents, or their affiliates, may be
customers of, engage in transactions with or perform services for us, in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with guidelines
of the Financial Industry Regulatory Authority, Inc., or FINRA, and unless otherwise disclosed in the applicable prospectus supplement, we do not intend for the maximum consideration or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discount to be received by any FINRA member or independent broker dealer to exceed 8.0% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of
business for which they receive customary compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_17"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of any offered securities will be passed upon by Mark A. Metcalf, our Associate General Counsel, Corporate Finance and Governance
and Assistant Secretary, and Covington&nbsp;&amp; Burling LLP, Washington, D.C., and for any underwriters, dealers or agents by counsel as may be specified in the applicable prospectus supplement. As of April 21, 2016, Mr.&nbsp;Metcalf held options
under our 2008 Equity Incentive Plan to purchase up to 62,700 shares of our common stock and he was eligible to receive additional equity awards under such plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional legal matters may be passed upon for us, or any underwriters, dealers or agents, by counsel that we will name in the applicable
prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom149726_18"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Omeros Corporation appearing in Omeros Corporation&#146;s Annual Report (Form 10-K) for the year
ended December&nbsp;31, 2015, and the effectiveness of Omeros Corporation&#146;s internal control over financial reporting as of December&nbsp;31, 2015, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm,
as set forth in their reports thereon (which contain an explanatory paragraph describing conditions that raise substantial doubt about the company&#146;s ability to continue as a going concern as described in Note 1 to the consolidated financial
statements) included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158779g13v24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:42pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:42pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g158779g96s57.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April 22, 2016 </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g158779g13v24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158779g13v24.jpg
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MP1<8)31#4U:"DZ6RT=0U56-EDI2BI+/"U29F@Y66T__:  P# 0 "$0,1 #\
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MFC3GO4%F6E<FK0RVJBV?3]=:T\B-) )C#$9/29>_TT[N>-<*!C /<!\1$WD
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MO3+_ $]JW&QK1*Q2I-G#0S\CQM *J"!9 IXT@'47=IE/7N/#BSFOLR@)\C'
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M,,_I\]XJI,6[7"ZM3)?,7I_O<H#V! [R1@11I!7GM6Y3V\'@+7DA#\=AL/"
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MC8B9Q Z7MUUO[?V/U.PV$RF7P^.W%C+%),EAY;L/J&*OE:]>8R0LK!X7FB2
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M2+:.1CE1@Z217<8KHP/AE=+_ "K _(@@C6$5]MG#!M(!;M$<AZYK.V(.Q?\
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M_9R3"'L<J#9(RKQ6F2K-Z^KUT00337<"TBI ED1CVZTC(UR.9IG4+@-S]/\
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MKBN;-NKRX[7(V(X1TYK%NSLMX;E<(E6:*V0R[^.K],;+IJMW"9;/-1TH\8+
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M\[VR _1K8X?_ "<3?Z]7IZ&#CIUBS^E<RI_ZPG7_ %:FTR-M2]J'CK,]1TW
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MCY8GJ14FGW[><>])W[=^WDV4+W[?GV[_ &S])X=#]S+_ )QKYR^8I!]\;_\
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M !,(%$?X&]F![#[EXP:\,8/V@'Z+&[C^H.P]_P!0YMGV!T8_\XTO_P"[M_\
M_?6D?NG]H/\ \TW_ /\ SU'_ ,/KIE@Y@?$P()'$VMM_L"]A[C7^'.OYA4 _
MS"HZFG%!$/R\"B;]7?/3#M_HP2/[,Q+_ ,MN&W&/'W\WXA_/KQS[I]H-5/./
MS:#SR8-JT93^SMQDQ_F'.KF^IWMFDM6:TD;H5\6XR&OZ:]MA92/+$R9;,ZKL
M:O/%D8HC5D2,?!**.@=QY630K)QZC8K5N"8)$KI?6%+UQ*W::Z6["P%&[T,*
MS.(NQ^YN]>P+VMW-W#@]QYYU;'&/8DQN/>WW^]O1J/:]1!%)[PT$9G]2,*@C
M?U"W<@1 C<KVKQP.Z2/;Z>_[_;Y-UW[??MZ!^_;/,GY:_P!\O^<:]<G]K?\
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M^P#.4>_]H9J?6P']S.-/T&=@!_6<?D>/\QUO'LZL!O#+K]6VW8(_4N4Q0/\
MVAJ])E8M7)TQIK&_F0X2:\0^53I?MZ#;C?O%PMW[=O21UC:%%._?V[>!1[]_
M;,QMT%MP8)1\SF,8!^LW8 -8#=;!=K[D9ODN S#']0QU@G^C6J?R]&N:VMA3
M\.Z=P;IDZ\*MY>FGLO;Q&G?OV^7&WN5#>/?^K\T=S]O;R\OS[Y4SJYQ^[2WQ
M\S2Q_=^OW<#S_P WMU>;H46_V/*'/R&0R@7^]][<^/\ G%M2O\A]!:UY0Z9O
MVB-N0H3E#V'!JP\JBF9-*0CG!5$W<18(1THDL5A/UV6;LIN#?"BJ5K)L6RBJ
M*Z(*(*:)B,K=PF1JY3'R^E:J2"2,GRCC@K)%*O([XIHRT<J\CN1B 0>"),SN
M$Q^XL3=PV4A]:E?A,4H' >-N0T4\+$'LG@E5)H7X(61%)##E3K9>H%P W)T^
MMTOM:['9K3%-F%GTAJK:3%DJA6]BU=!8H$<MS"99.+LT4FNV;6NK+N%7D(^5
M2525D(.0A9F4N-M3=>.W9C5N4V$=B,(E^BS S4YR/((\%X)"&->< +*H((25
M)8TH#OC9&6V/EGQ]]#+4E+OC<DB$5[U<'P1\Q'8C!5;-8L6B<@@O"\4LG9.G
M/U']S=._;2=MI3AQ:-6V9VQ0VQJ%^^40@KG$H&]/ZC'&,59*!NT0W.J>OV5!
M YTC",=*(2,(Z>1ZWQW?L_';NH&"R!!>@5C0R"*#+6D(Y['^1EK2'CU8">#^
M6A255<??8>_LML3)BS49K&-L.@R>+=R(;<2GCU(^>1#<B4GT+"J2/[7('B9D
M.QQXZ<A=6<J-.4G>FFK 2Q4.]1@/F"QRD0DXI\B<S:7KE@8%56&+L5?D4G$7
M,1YE52HO&YS-UW3-1LZ7I_E\3>P>1LXS(PF&U5?M<?-)%/F.:)N!WPRH0\;@
M#E2.0K J+ZX'.XW<F*IYG$S^O2N1]Z$CMDC<'ME@G3D^G/"X:.5"3PPY4LA5
MCJ\N46NW.H^2O('5SM S9;7NZ-G4X$S%$H"A7KG,Q;59/N >;=RU;(N&RI>Y
M%FZJ2J8F(<HC=K"7%R&&Q-Y3R+>-I6>1]\U:-V!^XJS%6'S!!! (USIW'0;%
M[@SF-=>TT<MD:O'''PP6Y8U(_BLJAE/R*D$>#JUS\+!<476M^8&OQ5 '$#=]
M47$B F !,C;(&XPJJJ91'N8$STM$BQBAV)ZB &$/4)W@KKC7*W-OV^/$M:]7
M)_&"6O* 3^(LGC]3:LM[-UL-C]TT>?BAN8VV!]>+4%J$D??P:@!^[D<\<CFV
M#D$:LQIC35<SXFVXI0G!'6]4(J4'UVY)5!,4.X 92)KM$V/+/E@#[B5"2^A$
M-V#L N"B(A[ ,O\ 1:N9-T7)^/AK8:P>?NDFM4XT'[4]4_\ -U WM#6Q#LNA
M6!^.YGZH[?OB@IWY7/X@2>B/UL-45H.&DK'-0]>AFIWLQ/2D?#13-(.ZCN2E
M':+%BU3#\SN'2Z21 _\ ..&6>ED2&.2:1@L<2/)(Q^2HBEF8_@%!.J:0PR6)
MHH(5+RSR)#$@^;R2,$11^+,P _7K;7T&JMJ)1:72&9@.TIM2KE5:G*'8IVU>
MAV<0@8H#V$ ,DS*( (!V >V4*M3M:M6;+#AK-B:=A]S32-(1_.VNG5*LM*G4
MIH>5J58*RG[U@B2(']H74;?6T_HM^6_^BE(_VLT#-QZ:_P -\!_+VO\ 0+>M
M!ZN_W.=T?X+4_K*EJ.[X7@!_N.]^&[>P\EGX /[2ZNUP(A^X#!_KS;NMO\(<
M5_B9?].N:T/V<_X*YL_3]T#_ -&-H?\ >-02]?[CK_ 3U$;[9HQC\I5.0E?@
M]U0XI)=FQ9R6!S7;\@*P !%'[FZ5Z6LKQ/\ G$DK,R,<!*LF<\G]*<O]J;1J
MP.W=/B9I<;)R?/I1]LU4\?116FCA4_(F%N/D0(9ZWX'[&WW=LQIVUL[!#EXN
M!\/K2=U>ZO/R[VMP2V''S L(3X8:S Z.+H.7O3VZA_3=DUP>6)U4U-TZ;CW"
MOFHK/K)1QD$D2F$#(14%M&D:RD'":?X#.+:^4#P57.*FO]0U_<_NW:6\4';"
MLXQN1<#@"(%^2?H9):-FZBD^>*ZCY <;5TH8;IV-OK8,A[YVK'+8J-C\YV$?
M:!^C'#DJ>/D8#YFRY^9\V,NC-QK4XP]/31=7EHQ2+N>Q(MQNN^H+H&:O2S^R
MP;RT4TD6JA2K-I*#HZ50K;]NN +(NX54BI4S@*1(AZBYD9K=N4G1P]>G(,;5
M((9?2I<QR,C D,DMHV)D(\%9!QS\S//2?;YV[L;#5I8S%;OQME[JLO:_KY#M
MEC212 5DAIBK7=6\AHB#Q\A0PZD@B/4&YL]Q$?\ PI=YA[^_L&Q[" !_8
M!^H [9:39W\$]M_XCQG^APZI;U _ASN__*/,?Z=-J\+T!3 /2MXZ@'W),;L*
M/]H[SV*;V_<8,K/U5_ASE_QCQO\ 5E0:N%T2_N;8'^5R_P#7-_4IFY*@IL+4
M.U:"B4#K7C6]YJ"1!'L!E++6)2%(41$0  ,9Z "(B';O]\T?'6!4R%&T? K7
M*M@G[A#.DG_VZDC*U3>Q>2I*.3<H7*H!^IL5Y(@/YWUJ6E$U$5%$5B'252.9
M-5)0HD434(82G(<A@ Q#D, E,4P )3 (" "&7T!! (/(/D$>00?D0=<QR"I*
MD$$$@@^""/!!'W@ZOV?#86)*:Z=#V,34 RE1Y";-KZY._<4SNH2BVHI1#O[>
M25E3.'V ?(?VY57K'"8]WJY^5C$TI1^(62U!_GA.KL] )Q+L-HP>35SF1A(^
M[NBIV1S^L6.=6 <BG4W:8TTQIKCY4X)Q<D<0[@2/>'$ ^X@5NH(@'^K/TGET
M'\9?\XU^)?$<A_B/_P!DZU#^7^URZULF8WC%7N9/1YTMQ[L -6ZM^X4Z!"JR
M[H@G)6[[$ZEIDW1K%Y$**Y48JSL8U:13;BFJ]B!D(T3@B]5*:G+YN7;W4+(Y
M>+N(J[DRIGC4^9JLE^S':A\^.9('<(6Y"R=C\<J-7_3;L&Z^EF)P<_:IN[1P
MGNTK#D5[L6,J2TY^0.0(K"1E^W@O%WQ_)SK74IJ;"T-M<BA0DJ/M73>P2G #
M ",O4=@:^L8#V,'XRIR$%88CL8/Q%*X:B'XB_>W9]TRE#CX+5#(U/UQV*EN'
M]G*2PR?@>&U0\&]A<F#^^4\EB;P/GX9:MZC8^OW20SQ?^TNMHKPXY(UWESQC
MTUR'K?RR2&R::PDYJ,:J"JG7[BQ,I#W>M>1C&4-^CUMCYF(345['<(-$G0!X
M+D$:2;AP\V S61Q$W)-.PZ1N?G+7;B2M-\@/WV!XY"!\BQ7YC71G:N?@W1M[
M$YVOVJN0J))+&IY$%I.8KE?GYGT+4<L0)\L%#?)AK)C,+K8-:\7XA/7;JC]3
MG:DZJ@9!GM:BZGV)%]RB4BK9&DQVNGJZ7M^(JDYKZ6%0P"/=?UO?V[!;;I+;
M6SLJC$#RU"U?J/\ >&-E[B@_JCMQ\?AQJBW7.@U/J'DIB"$R=+&7H_'@JM..
M@Y'W\RT9.?QY^NN[_#?W%&L]2)C"JJ@F?8FCMITYN03=A769&K>P#)%#^L(-
MZ*NOXAW_  HF-_5[AYNL-<S;.:0#GW3)T;!_ -ZU3G^>T!^W7LZ!VA7W\D)/
M!O8;)50/TBAKWN/YJ9/[-; /*I:N[IC36!_5"N"-%Z=W,Z=75! '/'C95514
M$0+V>7RO.J,Q HCV[*'>V-N1/\_4,7MW'L&;1LFN;6[MN1 $]N7I3D#]&K,M
MIOV!823^'.M+ZBVQ2V)NR8GCNP60K D\?'=@:FG!^\O.H'XD:U?^78USKULE
M^B-KQUK;I@\6HQ^@9"0LM<MFPW'F42&6:["V#:[; K]A /PJ5B5A/3-]CI@4
MX#V,&4YZE6UN;VSCH>4AFKU!Q]&J5(()1^R=)>?N/C5_ND%!L?T[VW&Z]LEB
MO9OM_&6]>LVH6_;7EAX_ :E9S1=25K'3E/Q7TSS'TY9-([QK"5AJDZF*\>_0
M]%O8Z?8D$5DXNWT^74174AK'$&74%LZ*FLU>-E7<3+LY&$D9&-=Y?!YS([>R
M,.2QDYAGB/#H>3#8A)!>O8CY DADX'<OAE(62-DD1'7 [DVWB=UXJQA\Q6$]
M:8<HXX6Q5G (CM592"8;$1)[6 *NI:*59(9)(VULO/+A7L?@7R*M.A]@J!+-
M6R25BU_=F[4[.-O^OY5PZ2@[,S;G.J+-UZK-Y$3T7Z[@(FPQ<K'I.WS1!M(.
M[C[6W)3W3B(,I4'ILQ,-NLS!GJVXPIEA8CCN7AEDB?@>I"\;E48E%H#O7:-_
M96>LX6\?510)Z-Q5*QWJ,C,(;"KR>Q^4:*>+N;TIXY$#.@61Y4>@=U$8OB3=
MMT:JVU./$M*W6J(WZ)9@J50(79\%,5^OF7C&ZZJ2" 6BK2RY9U4IO4<&J%>*
M!?%N<V:-U4VC)GZV.OX^)3DJTYJ2-\O4HRQS2\.0"3Z$Z#TA\A[Q-]XU)71/
M?<>V+>6QF4F88BW6%Z)>>?1R,,L$!,:L0J^\UI3ZQ!Y;W6#QXUP'Q%O&![I?
MG(INB-CCHT;DY5X^WM7:20D8H;!I[*-J5^B"#V["[40;UBWO#B8?6<7!82?S
M9RD^O2'-+D=L#'.X-G"SO792?C-2PSV*LA_B@M/77[A7'/T)\_7C;KXG>)R\
M<?%/<5:.TK <(MZJD=6[%_?%5KVF/U:TW'R/'8OAJ]WM==\Z++JB5>$;L-^:
MCL$'$('4],'5VH3IK>8<.YA\#"6J1]\33)V]0ZRZ14S=Q$BGRZR8QK>V(;\:
M\MBLA#+(>.>VM:5JLGX_V]ZI)^X'D?4>CV?LPM'>5C&2/VIF\7/#$OR[KE)T
MN1?AXJI= 'S+, #]#?1RK6KI:8TU2\^*-W>TFMM<:./4:]*HI0*3;-I6ANBI
MYD*_V)*L*]6F[P $2I/8^-HLP\21,!52LK$BN8!2=(&&QO1'&-'0S.7=>/>[
M,%&!B//93C::8K]ZN]J-2?D6A(^:G52_:-S"S9/;V#C?DTJEK(V5!Y'?>DC@
MKJWW.D=.9@#Y[)P?DPU&#T1N,#[DSU!]. XCCNJ1I*03WO>W1DA.T0;:_>-'
ME08+^8>@L::V"M56"K%0WDXBC2[@J2R3)P3-UZE9M<+M/(\/VV<DAQ=5>>&)
MMJRV''U'IU!.P8#Q)Z8Y!8'4==(-NON'?.*YC[J>'D&9NL1RJK2=6JH>?#&:
M\:R%#Y:/U6X*HVMD#E/=7YU%7UN![=+;EL/?M_BO1 []^W\K;NO2]OW]^W;\
M^_;\\WKII_#C _RUO^K[FHUZO_W.-S_X/2_K6CJ/?X7DHAPSWN?V[&Y.2Q0_
M7W+JO6 C^[\8=O?]?[]LZV_PBQ8_]2Q_Z=>_[M:/[.G\$LR?_P!Q3?U9C?\
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M>J DUWJ5+##D]JS1S/&A ^0+I*X8CRP1>>>T<5I]I"K7.-VS>(46X[UZJK>
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M)?\ V]T:W)W_ '>7?]O;MF]=,_.^,#_+7/Z,=<.HUZP>.F^Y_P#!Z/\ 3EJ
MU@-\+V3MPJWDIV_E<HYXG?O]_#4^IC=NW?V[>IW[]O?O]Q[>VU];#_\ J3&#
M_P!21'^>_?\ ^[6D^SI_!',?Y23_ -68O_OU.?RST7'<F>,^\M"216X%VEK6
MTU:-<N0 48RR.HU5:IS8@8!+YP-H;Q$REY ( JP((@(!D88')OA<UC,JA/\
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M@7M,P<GL;PO'S/.M7WIMU]V;9RFWX[2TGR*5D%IXC.L/H7:UHDQ+)$7[E@*
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M4Y:8TU^:Q#J)*D35,@H=,Y$UBE(<R)S%$"JE(H4Z9C)F$#@50IB&$.QBB41
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B8D2O5D'GU*-$&2.&0'@K--)9GC8=T,L7)!FLR-]2WK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g158779g23h26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158779g23h26.jpg
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M  (1 0,1 ?_$ !X   (" P # 0             '!@@$!0D! PH"_\0 -1
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M:DACQ"8=E%4P:GD-.34M- JDA+Z%RDL%)9!4[ET-%!;&=FW;RI@^D_1>T/\
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I\4H\4JM5%_S4^Q7^EWK=_N7>/)[#XGY"H[GX#YFK*^14T>*4>*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g158779g67c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158779g67c03.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6K$:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S8W8S S/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,38M,#,M,3%4,38Z,C0Z,3$K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#$V+3 S+3$Q5#$V.C(T.C$Q*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,38M,#,M,3%4,38Z,C0Z,3 K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R
M5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H
M/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:&5I9VAT/C$X.#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!
M0D%G14),045S04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!
M04%!04%"04),04%!04%%028C>$$[05%%<T%!04%!44%"+RLT041K1FMB,DIL
M04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$
M06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'
M>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C
M>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%V045!07=%4B8C>$$[04%)4D%1
M35)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K
M2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O
M3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I
M8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY
M63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+
M0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C
M>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1
M645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-
M2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G
M2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2
M;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A
M86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9
M<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867%G.5HQ3TA3.4QU8BMB9$QD0W=8
M<'EB;W$O-TII0FQ'<'IJ1FI->C!B=%!H3U=99T]R15!Y=SAX>E@V6'1J9"8C
M>$$[>6,W;%I'=6\R4%5R2S%:0CE$;78P-7 K=SE98V=L0U(Y5CA8>C4O8CDW
M='4R3DE)8TUO:F)L.'58,F9C>G9.*S9.,DMU>%8R2W5X5B8C>$$[,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMV379Z6#$W;E!$;W-,9B8C>$$[1$93839O9C)Y4&=5+TEB
M+T%%:D]7-V8Q9&M9:# S4#9(<$]X3DY13U$Y9&=W+WEZ<D1A4G)D<F9!;C T
M,S1Z060T,BM&>#EX,CDX,"8C>$$[,FDQ2&<U67HK9G5D='$X2&DT>D@X5SDX
M5FQ:47EK37)#;TDS0D)Z,$5',VA32V)W<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1E50<4XY1%E71GAE>D@Y,V)X=$DS879%5G Y4%1+<S)5631'4B8C
M>$$[-4%.;4Q'6GE%4C%F4#$O9EA.+V5Z6&QY,T]E9&DW;C-0665W>GIZ3&QL
M:VM:4S5L-W9&:D5):4DU0D5A3%EX,TYY,&QX=%I7:4<T=28C>$$[>C!Q:6M!
M25 X<#))46903$Y.:45P5V9P:G5F>#4X;7956D1'3D0V<&)$.&583C8S-4$X
M>'EA,7!$;31)3C5B4T9*44YV:%EL:TE!-B8C>$$[0VYW+U)N661K-G<U.&9Q
M*W%*+W,O2&LX=#)N<$)H>6)F4U(O87EB3F\V,3)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W90+W=!,DYC.4LP9S!E2G9J=4M46$9$*W=P*T%(-7-++U)N
M3SEV-G%O:B8C>$$[14]U-3DS-"LU,S-9;6UU4GE(<'-(;"MC<3E);C)P<BMI
M.4%T3D]!2S-E;T%8;#ES45)(56E#4&8R<34K:DYH;DAH65EW+VEN-G!E-R8C
M>$$[*T5F<&-,0V9%>6UF.$UF4U Y.&8P26XX=DYA+U)N;4M*2D=P8C-V*VIY
M,39!<V9G8B]G='9K8W,W2#%0:%IG1#E-='8Q3F9A=6XX5"8C>$$[0V$U>#,O
M5SEP>G5(:FY9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T97<$A33D=K8VA5449M
M63E!0G538T))07-P04I.0C1(-6LQ:#E8,74V=FTK>$DY25(T4G(X2T0W:'8W
M-34Y<F118S)752LO;#=U:B8C>$$[,T]K=T1&:D5F>&%-.&LV0BMM9&-I:&M7
M='!#4%9U5#(T1#EN+UI(8DQU>DY*-#)502]33GDP.6]A;G=C4DDK;SAM6B]M
M=&]9;# K,R8C>$$[,5=&2TYA2#!:<40O04A5-2M(+V=7,BMN3C,R.7!B9TUG
M+V@R4'4O2#-U;S=&,4Y4340O1G8X9G@Y>GDP16=G9S!),T)'8V\Y2WEY*R8C
M>$$[+TUZ>DYC4E)X47E*86A55EAE3E%89&=.,DIA=$MN=WIB-64R.#AG041W
M=7)X.6M966UY3%-V5'18,5,W,3)W:W5B=6%::F-X8G9)>"8C>$$[+V)(4W!Z
M17<V:DI03$5Y:U0V:#$X,TMY-$E2>%-%66=E:SE(=D=E9U!$=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,B8C>$$[2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMS42]-,U=V<4=G1S!J86QX9G0V5WA)26E'.&@R.&1L*VY.
M3C(S<69$=SA)-7HR*TA8.28C>$$[5'1U>#E0>#5E23AO+V8P95!5>FI(<DAS
M9C5:-DXY43AV:35D8518-V5R53%R-EE&27AV.4QF5&YA9&EA8G<X4$5E8SDO
M:# O2&TX;"8C>$$[,G9Q3U!,=VIL2&(T.55L+TUB>G%L2F1#<T-R,2M'*VUO
M1T$X63%R,SA4,BME65!B4&%F4$1$+T]0-DA--TLW4#5:6F9$.6)Z8D]:928C
M>$$[:&-Q;&E!;W%4<T%/=4E#<V<P;GDS<DU,4F%T8U=Z=U=6;S94>5!)<D%L
M15!-;%)4=T=B1$)O<W-A>45%4FI28TA.<3A:=D=#1$M7>B8C>$$[,#9Z+T%$
M0CAP,U1"0F9#1GHR;59O>"]W4DA(.&,V<D@R=G U+W=!5F4O6C5V2C)8;FHO
M1&9U6D)(3$A+:7E2=4AJ6596,4E)23EI328C>$$[,DU:06EW-$)"0F]R<TM(
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6&E8;B]75"8C>$$[<6YM3V9G,6)E,"\P945F-F@K32]3.6,T
M6'1B52M,;DYC;S=$.&4Y-TQS>E0K2&A(9DQD0F56.49B5TYC='))06U&:4AU
M1#!P1W4W.28C>$$[1#E!>6I1-F)X<V]H,#8K-74Q;6\X3$5:9&5N=F5S960Y
M9$=H-D$U='%2,TTS-VDP0VI:5%1D:%1P>%AP;E@Y<#9R=TU0<"MO-T0X928C
M>$$[5'DO6C)M.&),=GE'-65)<WA9;&U*3$4Q2E!5;D]&2F5Y9'A.3U90:$=X
M4&%P>'!687AV2G)+.&=U-$1384(Q:U$K-FUU5'A:1$-1:R8C>$$[3UE,1$I!
M5&E9;FM8=%=U,SA';V533'DY9TY9<FEZ85)E.4MR=40W9S=(3S0Q5U5:3DI+
M635'1'@K;7A(2'%9>%!-4V5(-7=J,F%B*R8C>$$[6'9.3W)A2&-"-U=5=$%4
M5U<Q8S%J8V0Y=7@Y>&U:;SEF:W='-&YB=39/3'%T1FIZ0W!$9G8V=F%.0C$R
M>3%R5&MV8E4W2#1:67HY<"8C>$$[2$$S534R*VLQ56,X0D]0.6IX*W P,'--
M*T=3635K=4\W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T98628C>$$[<3=&6%EQ;%AM:E92<&5H6&0S>3130D-S2C<X,S)5:G!7
M;EA-5%A:+T-W>6PQ-D]6;W-0:5I9>#900FQ"2DQ%,5!V=5-4;FXT931E<R8C
M>$$[9FQB;W!T9$MK,4=685,S8F-9:65V<$HS1R]2;7(Y=WIR=7=T3G=9>DTX
M-69D+V$X=#)Z<4]+66=/569V634K8D8X.'5U=U=N*S8W828C>$$[14=N*UA)
M4U0O=T%+1GI7.78U4V-O:C!I4'8X07=(661I639X1UAE5T5:;VYC=E=R2'E,
M0U!).&QI67@K:W)Q35A$>4AQ2F@X56%B.28C>$$[3U R5#E/9&9I-TM(-5%W
M<C%Y1B](<"MP-6)*,FMF>DEL9F]I82M(6#EB>59L2VMQ=TE91VA"-F<U>4)$
M,4PP,SAR9%5I=DY/=3E#=28C>$$[=W-Q4E9K:FEC0F<P5&UJ<E$W541B+U1N
M561H6GA/17--=#8K-#@O>#5V3V1S-%1#67EX,B]8,"](:WE$55!Y*SAQ,VM:
M6#9M3&0K,"8C>$$[:T)+1692=78S:DYJ;#=),#AX.4YE-7=-6&%M94(K<2]E
M.#0X,F529%$P2"]!16A'*W1A95115&=52T4Y0DEV8C4Y335R6#EL>C K-"8C
M>$$[.55/+SEB,$]I-U-H;C(U5#=V,4LO=T-7;71Y5TAM0DQ2;2\P82\X03-4
M<C)%9S-J8C4Q*T@V8VXR3'%4:GIC4#A-.79J,%ED<C9C5"8C>$$[>&-85T\O
M-C-S961Q.&DW1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3AZ+TYV5FE:<E!3-"8C>$$[-5!H4E103V<V5E!W<%AF
M<T%C-68R9S%'.&-94&UF,%!2.6@T3G!423AG=S=19$1U=%HQ3TMW=&%!;C1P
M6D0P5E(Y;SE/,S8X,'5L,"8C>$$[<W,R45%I-V95-FE/1T)L2C=Z8G=25SEV
M1F)X1&I&17%O:6EG;W%I9S9:-D)#06I%06-G.%!/4FM35'I,>#<X>6QB+T8Q
M>%56-5)X:R8C>$$[5DDK>C992#9W8S1Z=&]F-%-F8U!U970W25 X06<T.34K
M.4HO3$YQ=#$U:# V0FA62'5)*UDX5D1!;CA";49O<V9(;6=$+T]$;#9U9B8C
M>$$[1&EK9DEV9F,Y0V5&94PO;4QO=C9..'A3>6]V1S)V=C,X6C=C:B]E1"]G
M="]P>FE/,DY.-%=9:V943&8Y8C)(6E=O.%1#065C9'8Q2B8C>$$[6#59,6AT
M2#%Y,79Q;C P8FI/0C-J8C18+T$Q2'9M2F]D4C1/5TTK;E@S3U1R34AI-&I(
M-64Y-S)R2S9H;$E+<TMQ4C!)3V5G9S(X3R8C>$$[4E-Y-71O3'$S:W0U,$5K
M37%L2D5047%D:F=N051I66YC1DU*;4I"2$U0151P8W5K*V1O8D)34S%V97=I
M23EY<&17:DY017%2;D-E028C>$$[8T]Q14\V62LO6C=0>&AL,'AL,WA0,V)V
M8W,W,31P,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,B8C>$$[2W%D>F-25S%T3&-3;6M52TY*269"5D94:UIZ15EM4C5"
M;$-":U%">DQW2%<Y56PQ6%9R;E5(2$5Z=5=23W9&96ER.4%Z>GI5-7IL>28C
M>$$[1UHV;#=R5#12:7AI03905"]W07,O3#1S3DQE+VLS;G9A8V9A3F8V=&Y6
M9&EA5'<X9D=E8W9U96(W63%82%!G2$M0,W-Z>F1U;F599B8C>$$[;3%9=DAQ
M3FIF:6]J;&HY2GEU,WA235=(,#!F8C5:>79B*TEI8UHY0TLK6#ER,'9995,T
M4V@S2#<O=T-X:2]L2U-/1'I0<')U84E,:"8C>$$[1DI/,4-X-&HX8S%86C5%
M8SA#9C5Z<W1C0V--9U U<C-F3R]E25,S5R],=6QA,T9&2'%%4FM71FDP6D1&
M4T-243=G:G)M3'%T2&IZ9R8C>$$[0UEU;DHP*W%Y65-403@P;R]W0U9:*U5F
M*U=A5"]K82\Y8W<O-44P,V-F;5A++VQF4#-J-4UJ<S=31S!T26)71W9O=TE)
M-'=X3$5+;R8C>$$[;T)5*S)B4$AJ14EI235",2M36FY)>5!-<3)465!/4EEF
M<&(X,4IP54A+,S X>'E44#(U>%)Q1DAZ.50Y4GIM=D,X8G1!:V-O5F9W2"8C
M>$$[-C-O9D8X3%%G2&Y++W10-FYO,F1+.#@W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E='+VUJ<B8C>$$[071.0E=X
M4G%46#=C5%1R-F-D1V(W>GA(,#5P3S-D4G=994%C-2]C2&(Y:EE/4$QX9$DO
M97AJ>4PU2V)52C!V<G=-='!#43-&;$9*1R8C>$$[3R]%9&1G4'1:<2MY*WI0
M14EN3#92.78T-G5Z-U,W43A-8TUF<5 R4%=&5E952V]O<6EG039!1$]U07 U
M56TR.$MP6#5M,%).6C!E828C>$$[>C(Y56IN07IB05-$<# X96AZ13%U;4=B
M1UDY96YV8W)2-FIW8V=L,#8K-31E.79C5TXV67!X-DTQ=2]&,6)C<7EK13=B
M.40P.&,T428C>$$[=T]/5DA9:#=-4T4T,DYW6'9/:UAN,7I43&$U<40V<V%S
M4T152&)Q1'0Q>C!$5#5/4$=*9#1E2'HT*T-::C-&1C5C,4]X5E1U8FE',B8C
M>$$[='!B;61U14U#3DI+.4-A2V<U36%#<#9$27IM27A-:GE'-TM%1$EG1&U7
M3#9L*UI8;'%',FLK<%A1=4QQ;D=*5$A+141(64UX2VHT4B8C>$$[,4Y..#%/
M8G1R0D=*-%1C=F-F,4]Z=SEK6FI)8U%Q4'9#0SAU*UHO2D=J,FIO9%0Y83AU
M2$TQ-V1'1V5S:VIB:R]9-D-U=WEN4C8W4R8C>$$[-%DQ>#-)-WE.4S-0>6)T
M6&\Y5&QL.4921W=&:EEF3DYF*U9J951T-C,K-#=E:DUF,4IM6"],3VTO;F99
M9C%/3"]*5V\O;2]A4#%T2"8C>$$[.'@O2G=P4R]*<6%B47IB92LV65 U6C S
M.#<W1"MP9C5*,4@X,S=2*W1-3$QZ4&\Y.$5A>F579%@K=WE7."]%-S K,%4T
M.69%-6LT.28C>$$[9&EY9E-39C@R6#9M:DIO.&M0<6]F-3!F,7!Q3GAM5S1R
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<GHV.28C
M>$$[,'0O3E!N:6-/=R]2=6IM3T]52&9K86QM4VQA9D5W24HW6GIM6$%D6'%Z
M9C!9-D@W2&99.'<P,FU(."]*8E T;VMI44EG;V]Q45!M828C>$$[;D]I:D5!
M54A24VM38DLW0V@R2W5X5FIF;79Y5EHV-G9R27=T-SE24515<7)G9$))3SE/
M>#9J3EIR*WI9-3EX=%!V.$$Q=7@P6&%%<R8C>$$[3W@S:BM/5$9D33%J>DPU
M3VU7>C%A,6%B4VDQ161!3TLQ3S5J669$,W%63V%N0G%C*VI01&MJ95 X8VYA
M6G10:#%9-'-:<68T-7,V,"8C>$$[+W=!,&%"9G%$8C-S9DDP2'!U=U)W5'14
M:3%$6$XY:#$R2$HY36<V5$QO<W-/8U-M;5IB:7!B-6TO=T-58S%8+T%*9S=J
M+VLP,EEU="8C>$$[+W5*+S%*9F,U1VHO04PV2#E99F4X0GIZ,3=P,DMQ.719
M6'1Y85<X1'DY4'-+4TYZ>'%33VTK,E1H:6Q,:T-713AK63AZ5$I.4#AH928C
M>$$[66I+0SEL1S5+,55'-%%C4T-$6#1(-69H;7IW.6Q:<BMK9C999F],<CAV
M85='=G%0>5 V43E+,%112F)A,FI.-V-81#-&0E90<E9W-B8C>$$[3%1A9W$T
M0B\T2$]O,'5K35EJ:4UR+W)3+U<X-W%D54I34$-"6#E74#9K-WI/8THR2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMU3F%';7@W
M131Q;#)G-DIB-E!9+U8T;4UK:G5:8FED:%)P2D<K,'@O:&U.<$Y,2$1$:$<U
M-6LY-6-J539K-5I79F-",R8C>$$[0DUC>5A(9&ER1V9/2&LR4%=O5&-7<VXQ
M9E5K2'=306M*24(K>DI4.$1M<C=2-TY'8UA%,5 W+V4W3%%D;TA#86QV1#=V
M8SAG=EET5"8C>$$[<V)Q4S%U+U5H=4EJ4C0R2D)(.6YV;D=:635-8VI'5F=H
M-GI(2T4T.%5A24MH.5EU4#DK=B]W045C:'AY-S)F0T\U;WIZ:T5'4FE$<R8C
M>$$[45=/4$=E.65%2W5N8C9H83$S+V5X+SA!16AK<U Q:C-H:FPK9RLU.45:
M-E$X06AT57-Z939B9#)19C!Z9%%Y46@V5C0K;VA7=$YQ,"8C>$$[<FQ79DAX
M-#52+VY!:C5T;4A*=U1%=31G=D\T9GEF=7EF,S)P>&]T3FEK4F,Q*VQK>FTT
M*WIS=7-X.&YO2F1U>#924'I69CA!;%1Z1"8C>$$[9&18*TEF6B\P96TO+TDS
M2B]W0V@S+V)0.6HK,6@O3#,Y1#=F,DIL;R]W0U=&:F)/1S%'-6$K5E16665*
M4D\T,RM*:C!Z2C O66-)+R8C>$$[5V50>6-F4#)Z2U$Y03176%=U;39F84M&
M=&)A2T%!:V=2;W$Y9FM-,T=01$-(,&=",54X,#4O55-54FQR5S=&6%EQ-T98
M67$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1E5J.# K5710,2LQ-'EJ,')Y369U3'!25FPY;4@W4RLR64=U-U!H<28C
M>$$[23<W4S9&>F1&<G T2F)B>#9H9U O2W!0368X07DP,F8O0GDO.54X-3<O
M42]N-S1F32]Q9#4O3&U(=6PY;C8S9CAQ:SAX+SA!3%1:+R8C>$$[.$A,+T%.
M57-F.40K9G9H.'HK<% X=5EE-E@R9G)68E0X<69-34XQ1$LQ>&%&63-6,D%E
M5W1&24\S-W9*-"MW8W=K1&-D:C-N.51#9B8C>$$[8E=%>$EQ6#)F<F5Q-3%R
M>D1S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:28C>$$[<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ6#8O<C)L-D)P1GIQ,G%40R8C
M>$$[0WET5C534#%*-TMQ:G5Z2%E$2C0X6FUA2$YH:WE2:$5Y;'E$-6TX,2]N
M;#4X.#%A;W5N*UA7;#!U,&YK159N85=F.$%V5DMZ1VDX<"8C>$$[5BM0:V$O
M6E-G*V983GII,&5/0757-3@S;G,S84=826%J<U!,;3EH+TPW>5 U,3!Z>5)R
M3VYA.7%J4S9X<393;4-9>GEZ=&).3$)W2"8C>$$[2U$W.&QF8SA$.&IM0FYZ
M=TUW66I93S P*VYY1$9+36HV<&9:<SA9,4QZ1BMC4#59-C1L;&8V;DY-:$A+
M1EHU1W4W3V5-3G8V9G$W<B8C>$$[=C%P>%E:<TEW=S5O,D(K9W5Q;&MZ-F56
M12]P1#-J.'(O=T$P9$PX.#9A-TEN,516<E%,.61S4V$W2'!*165R4FLO4T1S
M97A/<C%/;28C>$$[3TDK5'5D2G)";4AD24TS>D=C>&AF-7DV='%7:R]L=')'
M;V%B8W9A6'-(,6(P<FE).%A8;F1223%$-W%X1UI/:VE*6D%$>2]9-&UU;28C
M>$$[631I46%/,S-V0V9Y."]04'I:<&YM1S-46#E2:S%(4F)L,6EV0F-F1S!3
M<V%E<D<Q3U$T9%-/:$AA=$-.<&XP8TI2.4EQ5'!T3C)H3R8C>$$[37AX1S0Y
M6#%50T-+:F-(;V,P5#!J<U9E268X04]19C5M87IO5B]P=6@V0F5V6C-A<CEC
M=G!O:4]60U-S35HV*T1->6MF>35S.41P-"8C>$$[>4)L25<V9G1,5GEG4D=*
M<G%51"]!330O965V3C-M3'IH<49V<E=Q5%@P165N=$MK56A(04]*;VQ$0E9!
M1F%-8VYR<TU)=T)!<F8X028C>$$[5S$Y;F%N2E!+4DDR3T@Y264K-7%894IF
M-6<Q+U,Y03!I-3%B5DIH0EI7<3AP2$\U2C9"5DAD;4]W1U1X-'I-,$]B6&MY
M4FA%>6QY9B8C>$$[32]M:C@W=E O;3=6:S!Z>30P=6U7,7A)27)/,'-Z4S9K
M2DY&-7I$-&=X.$5)2&I8<FTU>&%02&I&>3,Y-WHK8E@U8W-Q:G-03&XX,B8C
M>$$[4C)(+T%$:B]!4&U08U<V,VPY-6XK<39G-#5M25-Z>DUR539.2T=89G-E
M3F9M8W%L<CA9,D5D;DEJ,F)L27-Y;W-J.&E,*V-8;'9Z<"8C>$$[62M8+T%$
M4&-(5G1"=GA/13%&:6)G2SAC5%-#:S="6E99.$%/36TS6&HT-51M.$=C1$M/
M,&<S868X>&IY0T4O5D4S=GHV9"\V,W-7828C>$$[-3)Z-6@O3G(X=W9096<O
M;5)R1FAP,G5834YP0S!*:&=5:F=G;'0T-4])5F=W,DPU=3E,9VA,1T-12&YT
M6G%C:TUP06MA+UEM6&QM>"8C>$$[+U!F>F8U6E18=$XX,$PV3$Y)<V1S,'!H
M;%EX='A)*T-,:'9487):1$I,0FIL=VU,4$9(5EI9.%%L=#<O04YJ1U8O3T0X
M,W9+=7)Y5R8C>$$[1W%8:GE81F\T5S1S3"M*2$)P=4MU07-L0T151E@S1RM8
M9FQC57A92'EC9C@Y;GAY;VYC9$,K:69Y-C@O-E@U,C!%86QA2UE,;4IV4R8C
M>$$[=G).:E9O<&%6-C=C;&)Q<F0O;41M;S%'030U55AE-EA5:DY'>'HV<W!Y
M:'E73V5F4%!E:F543D1F53E22FMK63A,3WI19U-4>2]Y<B8C>$$[6&]",5IU
M=SA444<W0F=/4U9">#E4<5DT;S)8>FQ0.$%M3BMB2#5H-BMM;#929%,R;G)L
M=E)S8D)Z8GAP1T(X5%-Y9V@R540W4F1Q928C>$$[03-P;3-';GA9;S)2.#-2
M2%4U.#AQ:69G3FYT1G@K6"]!2GEF.'!94$LP97-!95EO;4QV<5AR5&A7<F-.
M3G@Y5VYQ,#1S1C9:<GAN:"8C>$$[-'9(6'!D<V1.:SA$9W8Q.2]W05AJ1VYF
M;7 K85AK4%A:9$PQ;657.2MQ=45U=$\Q1FI,5F5X:FU*3&=&5%93<D9E.41M
M>&QP<U=73B8C>$$[:C5H,45.6FUW>7%2=75H9E-0:VYZ<&\S;2]1-'17,'AZ
M>$HT6$9U,SDU1$M!0S!B+V9S931Z5%IS2GAY;W9186902$Q(:4-F6E4S328C
M>$$[1"].3#@R9$LX:E=I46E-6'5T,TLX<E=X1&-1<3%).5=5:F]L4G-/<F1"
M,TEY=$YP5&Q09$9W=%IR4FA&8S5D>GA44W12+T]4.#%D4B8C>$$[;&AT=%%K
M=#E/43!U5VID<E=Y:%4W:$=%9GA32'="-4XY1RMB2U5C3T%C="]T9%)#5V\Q
M0C)/,WE(-"MB,B\X04LW.'5,>GE26EA6="8C>$$[3G)-;7!P9'-S<E%T2#9C
M8V-O1D=:2W,U*TE50CAA1$YB<61137!"<7%D=F\Y26-)274W95)F.$%/4S-N
M2U,K.'=1958W95$O53E,5B8C>$$[6G)T4C!A-FQ7<3$X9E1I654Y,F)-+W,O
M1E5E3'%F=61:,G)N-' X0352*R\K>%8O-7AI.'%W,V5T86HU:G5%-41455<S
M<VE2<TIP=R8C>$$[96)J,U=-8V8Y;F<W4GE615)(5FPR5&AU4FUE;C0O2'9F
M4T=A9#-Z>C,X.69+<T]V9FPO9E1#34YE-E%P=G)6.7%H67A76F$K0FDU8B8C
M>$$[94E'6F5I>3A/441O9&Y"-U)W.&5);G)(9CEB-6DX:2MA-W9Y<C5P<V1A
M='EE345G1GI%4#DR45!T2VA(5&1E;F=A2'1M-GI9:$]*:28C>$$[6&YS1UDT
M-6E19F)L=F-1,T5%9'A!-&MH;5):27!&,T1+=W%P2'I">FUY2TY06$$R3$1!
M+WHV+SAL4')V+U)R+T%.4FM/6D]I+W92."8C>$$[9G5C4'1(*S1L.%!V1#5!
M>F](;#,R9"M56&U%83DK6&UJ6&)-1VYH:$9P8S<Q4'%7,S=Q<F4W2V]B-F,U
M,U8T*TA)43E6;W-N2&EI9B8C>$$[:#AM65IJ=5<K22]Z1#AX2'I&-3$Q9E9W
M,T]'-'5'5S)0+T9%6#=U3"]K;6=Z<$U'4&=G03AJ<6-V2&M-=3AV4G8K8UA)
M;%!M,U9P<28C>$$[;FML:'=!-U5E6D-F*TDU:61P2#!$,W5D,E1(.314+U(O
M4T@P=&UM96=F3D@O3U-N;D]7+SAX42M73&51+U5T2U9:8G!25VHS57$Q1B8C
M>$$[9#9(,#0R1E!!<S)B;G,O1%5E3'%F=65F-U5Z.%4K06-O+V5J+W=$;D=$
M>7!&4&5A;#5N=4DK4G1+5V1G-4912DA8;$UW.$=#1E8K5"8C>$$[2$DY;S5A
M06E/<E!S;D1:37HP,D@V6#!2;6]D-C=&6%EQ*U%F>C8O.&UX<G8O4G(O04Y1
M8T]B+U)F,U$K4#-V361O+S,X=F@Y=V4V9B8C>$$[.#0X9BM3=W-V*UEI-2\U
M3VY.8G(O=T,X9'@R6B]C:C1S2R\U>6PP2S)584QR<V%"8FAZ2EHS1&IQ-F=#
M4TMV*W(X9C,U:V1M>C5X8R8C>$$[4'1F2#E-=F=X+SA!-7AL,6%A,C@X6&5N
M8WE,92]S;DQ2,6]$3$,V<VIE.49,:C9C=3=2:F5/*S1T4%I5-GE%9#1F5"MA
M4C9&.&4O;B8C>$$[5#5Z;#AZ*V5,=W!)5S S5%=A>7-%0G%V1TYQ4U-#;3,W
M>'=46"M79S=:,$=K=SA%0C-L-6)86B]%>4AU1W=E=B]W1$].4&Q32W@X<28C
M>$$[>BM96EEX.6(Q85)O-%I$4V]T;T=+54AC8W!1,69'9WI!-U)Y,TQH-VYA
M9&Q986=:.50Y,SER,E!.8S=6-&@O>FLW-59I=4Y&<U!-,"8C>$$[35DK<S)5
M9W1,='=.,F=L<55,9C9K;7<O,3@R9EHR6&-X9% R=&AU26U/;3,T+TA6-7@K
M42]N2UAY.34T=#=/5GE.3S%O<EHS2U90128C>$$[4W-A45-5.%$U-#$X1T]:
M971X8V-036)U1#)F;CA024(P;'0K<#EB6F]8<&YW-S4R.'=82&U(>EAQ;7)Z
M<U=.,6-/66=F,EEL4$=*0B8C>$$[+W%O04TV8D9J-$EI4&,X9FUY*TI->3<S
M,34K5VUH,F5I*U)D1G-R5D%O83%I;FY99G1Z5$E*2DA*;TLQ6G1V86=Z46%M
M6FQK2E!E.28C>$$[4'!-66AI:4(S36UY:'E8=W@U=C%:=%@X,6%V<5I*279,
M>6%62SEK85%L0CE#,$=D3FIJ=WA!-V<X9&QN>'I-=3AV<&HO;DA,5&IA9B8C
M>$$[;'!"4%-N,2LV=4QJ='9X65%F.$%-:DY.,FA+.&YU1#!(6F-+>%@S:R]Q
M+U$Y4'I#9&EP6&1R1&0R:S%R34]53GA',%5Q*TMU0W)$-R8C>$$[:FAI84YO
M:TQ&1CA&5'=V1$Y*0S1O.&)&1TAU<&]C-F@T=#EI9FMT<7(V;"M75VA44TYY
M:VAH83%B=5%,85)O54(O,D-,;E V>4Y:4R8C>$$[.51O2CA71U!Y*U-'+U!R
M+T%-;%!R=CA!,&$O.5)K3TA29C-O*U S23=2+W5*9D0W=RM6-S-25$8U8C!Z
M5V\Y-')Q831T2G%6*T=71"8C>$$[9S1R+T%+,&-Y,"M78C!3.5)$>EIH-E),
M,VHX9DXW5"]!331T*UEF*T]Z-61K62]S-FAB3#(W47I(+VLS;70W4W@X<&9"
M,C-:1U0V;R8C>$$[9D@X9EDY4B].:GI#3D(O3#=78C57-'IV06)A,G Q.5<T
M+V1+4B]Q.'58,%IH85A(>%I!2%DV,TQW67!(.&)V:V%445I)9DMC3W5Y0R8C
M>$$[:3-D-CEP8F<W8E%20C-B,T)-;T@P2$XO>"MR:#AN;5!$.4A&-3 Y52]W
M0V-7+SA!;$HY6B]W0UE*9CA!:S9U65!A6#!$,W5Y-TDK<R8C>$$[*S4Y2EIP
M;F9V:%AZ4G%Z-G@U:S%45E@V,S$Q3D]",4%74GEY9U8W06)$3VYX>#199V1Z
M>#)79DA)>3=Y*V]0*V-E8D)B6#AS3$M9528C>$$[<F94,TYW,WI%<&@S*VE%
M6G!D9DLX=G5E:#=-:E=%2'9*+U8K:#96;44W0C)+=7A6.&<O;C$O-4YJ6&8K
M:E@O<41H>F8V3"LV2'@K.28C>$$[-6IT2"LO;#A0=40S5"]N2&HO>5=&;"]Z
M15A0+T%#9$]A,U@O04XT-VIS>BLU2'A9;B]Z;%!Q54LV9F]/;4%G>E-45%A,
M3#-655950B8C>$$[22]Y:35P.'-V-TYJ=5,T=F$X.6]X63<O04TT=S9*3F-E
M8F11,6-P+V\Q:&%'2&XO04U86$1J:5 K06IF3&4P6C%!1'9,4C)406Y)6B8C
M>$$[9$%(,$@U<S%6=$HX<C9V<6E%3$I:5V,X.%I*04A/3TYM46(K3$%$3E9I
M:GA403=Y-W904&AH2UAC0RM&>5-453EC-EHT.3ET9FQV628C>$$[2EEE469,
M,7-Q;&5.:&)U-FY9.#59>$DO669T<V,U=E5Y=DI,,W97-E-.66\K-$UJ>6QY
M1TDO;35P=S%$.'1F34U(.&QO.7@O,&I%5"8C>$$[+W=$379-:E-Y<DI&>&1B
M1&EW>4AL.3(W-'EI;&MH;%-73FES:V)",%ED47EM;T]D0SAQ*S<Y1C%&9%0P
M87<Q2E)28C(S:75!0EA94R8C>$$[;T@W+T%/=&Y-5&IW>4DW;G-C8RM+26PS
M:3-W-S5G,'DT,')89%$P,C1&2C=/-&QG:RMC8FQA:C).339A175)06IQ.&9/
M2$%413E.;B8C>$$[,40K43-N>3 X=RM58F936EI13E@P5TIB96%%,$108G X
M34UQ:G5/3D5B+TM'+U5:<$YD9TU:.%A35#!86C)O131#4#A59G4V4%1C=R8C
M>$$[;EEV9TQ/<65+9EE(-44X9BM6539&>#95=69V*W1Y,2](3D)R=C<P+T0W
M;G K>F8W:5!X*SAS.7I%8S4R2W9G,U=F.$%J<C,S+TU23"8C>$$[+W=!5$]D
M4DAK.&)0-FDK;U K8V(R62]L<V=*2D,S;'=&0C=$-%119E-C,'9A2#DU.$AO
M97DO-W(T<&XK9E@O:W Y9"\V3F8K;WE(2R8C>$$[.48O96HT+V,R9&\O,T5V
M:#DT95 K6'9,:#%R+T%*>#,Q:#0Q3%A';#9R2G%%44AH1D)%<W1F65)/-2MJ
M3FIK>6-/;TAN1W9T3'%-3R8C>$$[3&HP<W8V37(K=V9O668X06Q.-6DO=T%0
M+VU";SDX-VA,95-95W0P5TY&159X*S9:;3EK-4(O;WDO530K4$=1,&%03'=:
M66XX8G964"8C>$$[*V-O+TU.261'.'523CA4<S$O8W W3%=+2#=Y6E!U>D,W
M3G@X-69",E!A*U@V669(.&9A:W8U>6580C5C+TQ0>51P0EAJ3D(V<EA)+R8C
M>$$[-'9L4EI*9BM(8S5:<$UN2&MM5VY7-'9$=W=I=B]W0V-7+SA!;$HY6B]W
M0UE*9CA!:S9U4&%8,$0S<#=)*W,K-3E%-FY).%=M,V-K6B8C>$$[2W5K36I)
M=S9G:%-18S%%0G5(97I/>&9"5V11.%DK:W9,=FY,5G9+6#5$*UAD5#!U>%A5
M3&PU-4QD;U=$:T)(;G5'3&9"=C%11#9C,28C>$$[1U1#36UE44IR8CE4=3A/
M;VQI,#!415AU9G9K:W8O47AF;C<O04ML:4PO9TQN3% U4'@O>FU0.$%+;5@K
M8CDW2V9Y:2]/1'I,-3 X>B8C>$$[,U=L-FY95S%P87<R8VPQ1SA#>6@K4WEX
M249,3S=+4GAK4&)+3EAP230T9VDK8F1O9&903DUX3E96-V8R=EAC,3=T;GE$
M*V98+VLR3B8C>$$[9"\V3F8K;T](3B]O=C=O9D@W,VU/,&8W*UAW*S104G9)
M2#5H,C-K9CAM3DXQ1S1S2C<U8FDX=5E):$555D)*>EIL16IS87)Y0VUH0R8C
M>$$[=#!Z1GHV9GAC>$8Q<S4R;C%1=S9C16DW2F5B0U1Z1"MB=C5H2VLY>D):
M,U8P:%<S4U%V-E5514E,;4])04UZ3G@U3E1A<'%D<WDO5"8C>$$[9W@K461F
M8W14;#-)0DPV:#AJ95,Y3#AN95AO9$@P*W)H4UI,;35905!.37=!85)G3VY1
M041S04)M;'HU:FML6F5I,"M!66\X25,S."8C>$$[-#-:9GEY.'=&4U%F<3%+
M:G=,<4-0=4]4,&XY-D=V6&8S379C*TTX-D8U5CDQ*U9V*U59,&HO;4-T+SA!
M:S!U8WIL*W,K.'99-&9O2"8C>$$[=4-:-5<R2D@U.' O9V9Z1EAP*VI,>71F
M*UED.'0P+SDU2#-J-S-(,68Y,5 K<69U9D1U9$LX:RLR9GEZ;65B.'903&)U
M=D5J5'):028C>$$[4%I);%%(-E%T8S5V56ES:W9E.6)P1&5+4'5$>3<O;DE0
M.'$W:3E:+T]':7=M5UI%03%E,6I&5UI%1D)C2T)U94MG0B]A:#=(33=1-B8C
M>$$[:T0P4RM$<G4P=$=4*SAJ.&8Q=D)T0S$S5F1#,5<S,5A3<FAR82MT;352
M4W(K2W-/:DMW,DE/>$=B3V-"255E5'!S95%W4$9(66@Y8R8C>$$[+VQF*UHK
M;"ME3DI,<49T=%IT5D@V47-A.4-D=E5I<G59,E P<C!066Y1-FY42$=F-DPP
M,FLQ67I2+W!$;2M1=%9S2F1/,5,X,"M51B8C>$$[6F)/95-#4E-+14Y%-5%G
M:C5J3B]'5FEW.'A+2FE31#!F52\O041J=&9F5V9Y>'1)83$K<%A&>D(X=55H
M;2\U;EIP3F9'<VYV96HW328C>$$[;&5%1'5*+U<Y37I#9&=T;6QJ:&EE859U
M36-A;#-9.6Q55DIW9U=G;6YW4&-43E!C4WI/871+-T]X.3).5&Y54$8W.5@Q
M="M13VYM>B8C>$$[+TLO5$A9564W964T6455*S%+>4PY-F]$;6DQ,')Y;GEE
M;3=.:E=%961Q=C4Y9CA!:W Y9"]W0VI8+W%-:'E/:2]V4CAF=5ID;R\S128C
M>$$[=F@Y-%DY+WIJ9&)16%@U839H83-#0U-#9E5,:4MA33E'4C1)5EI4.'=C
M=C=13EI!4C-F<$QJ9&MG2$9)2"MD*V=0;E!Z2&\P*V@V+R8C>$$[<4=K5%8Y
M5W=U2DE#,SAW4FE&665Z1&-:=&]4-&]G.3=O.'509VM9;F\Y<V)Y-B]N-WI,
M*UAF;6AG6C=E.'11;71-45-O;3!X:3AN328C>$$[9&A-.55'83=X4$-J3U!D
M>2M0-FYB94@T,#AC*SAB+S5V-C!B+W=!-55F.$%(23!$+VU);B]W0TE,:T]Z
M96-M>G1F-EDO1DE0*V-7+R8C>$$[*U5N,6XO;4-8+VLV=5AD<&914&4P9&MF
M5V9C*VIR;4),:3-L9V-K2DUJ4G-2,6]W;V%6>E1G,&)D.%)9<#A%4WA01DLX
M56<T=D=X5B8C>$$[>#1%1VAZ<4AI,S$S*U%S-E,O;%9O;U5G=$@Y6E)W3WA&
M,4MF,45(3D1R=C<P+T0W;G K>F8W9V9(-WDY07I%8S4R2W5X5CAG+VXQ+R8C
M>$$[-4YJ6&8K:E@O<41H>F8V3"LV2'@K.35J=$@K+VPX4'5$,68X<B]+.78U
M<"])9#E$;4E5,U0S4&]3;B]D8WEY;&]N.&%"=TLP-V)::"8C>$$[86Y,=UHK
M2C)/;'=J2G!U2'9T."LV6F8V<#5:.'E16&EO6612,&TV1$Y#.5)34T8V4$<Y
M3WAO5F).<DE#8V$V1C!K6D=%<C9X3#=D,"8C>$$[6%9R4%=.27,Y5G-M-3)T
M-T-K.$HR<GAD46%';E%J;U(R3V,Q3T)I4T0P975X>D4T:5$U1DM0>D@P-#9J
M-4,X=U=I:FLW,DTW4G%"5R8C>$$[<GAO6D5(,'-O>7I4>7)*12MB5G%O.%=+
M43AN>$IN4U!*4'0W.'9R>$QZ>4HU975&8FYZ,#8Q1'0O;')#<75.+T)G4FY.
M-F=6:VPW>28C>$$[.61P5&5+4#E536=Y;'99<BMA=#AT;"M82&U+63!O.6I,
M0G8P<F-$,%(S2"LO3G-V,'-B>5(Y-VIA>5A$:6MF3#<Y;GA8;E)V2G9U:B8C
M>$$[>6I95&%F-54P5W=M57).85=&=$))<#))84M&54E0,&I/6GI3=5I)-WDY
M:&=I630T9SAW06TR5G1R-3 O4&8X04HV,C!Y2UAZ6#5E:"8C>$$[159K5W)Q
M;&EM>7AL>G1.1T]Y1FI2;$A4<4YQ,#(K:3%:;#9*8RMJ;V4P9$5)*W5!,C9V
M2R]);FUM-CAR*V$Y4#%M0FE%9VQ56%-!,"8C>$$[.5,S63!L42].96YG84A-
M-TYJ131M3')T4&U/3UEK1U@O=T1/45AL4U129E!S,2]';$Q,5VPK='A-06%#
M55579&$K4% T+SA!6D1+3B8C>$$[1&PT<V1D435885=(9WEK.4IB+W(O2&UZ
M4"]N1G)8-"]4,7)Y+TDY2#5*9C(P9FE#0D9-9F]P2&U.,FQJ-5,K1&PY:UIF
M<6@X9C$O;R8C>$$[92LU<6YD35 O3GI8-#E$+T%#.#%Q-EIU37,Y=3%N8FET
M1TUL>5!32$@S54U7*VI-:E-1-'-G*V)I83=*=UEP2'8R*V(T*S!B4V(S5R8C
M>$$[3E=T3DQS534S9#=+:T5+.754;6Q397=(56YW>F]*4T526C9035%G6D5!
M8WDK-61&,'$R,&I33$Q3-V(O04AN<UE)-V5);EEL66Q#9R8C>$$[;C-.2VY/
M6FY)>6M397(Q*T]!:D522%)H;C4Y9BM3;C$S+V\Q+W=#;WE(36I29C-O*U S
M3TPR:B]!2$5V:#DT4W8O;D<P069L=G-/="8C>$$[-T]4.7E:6C)H+V5F0G$W
M3"]U=FDX>2\U>5<X=2]54$]S1W-2<E-(5TQC1C(O=T-,-UE#3B]W1&MN-F5:
M=EHK4S16,T]V-U9X8T]4:28C>$$[+VY$-W9W1V5F.#1W4V%I,VLS56MM2"MG
M2F9%5VI%-SAZ16AL1E U4CA*2'54;4PR;%A'3RMN3C=*2C1$,U=G4"MC<5 K
M3U)O2"]-4B8C>$$[4"]X0F-L,F)Z:W<W6"MM4'A9+R]!331T<W8X06EJ5T9Q
M3U)S5DE(96=M5W8V.'4W4RMG93EO-TDK<RLU.4HU<&YF=FIJ.#5V3&-M9R8C
M>$$[+VU(<7-*6&IB,S!H=C=5,&]$2&-K=5%O.$9K-4HY1V1$<$UN1FI(>656
M,3),9WEK9"LO>F5V.$$O3TPK='A4*U9T5#!D;2]F,DXS-B8C>$$[-$@O1E9W
M9T%P.&YI879Z>D$W4V@V:$QV1'1/>6-L=TUE-"]E.6]Z5W4R9&ER<U9F25 U
M.68K5%DQ,R]O,2\V9S1C,RMI+W5H.&9V928C>$$[63=2+W8U9D0W9SDP+W=#
M8V50.$%Y5T9L+W=!>$9Z+WED3V$S6"\S:G5/>E W:V9&-4PO>FMD-5)':V5C
M23E:=#!#,F5T;UI(;TM!6"8C>$$[359&;#9F>D%Q+W538WIT0FPT;U8Q:39V
M=%!$=S5/26-P9F5Z8B]N1UAZ:#EB,&4X.')81#%M,#1M-G-G5#%T-5<O94M0
M6DI46"]:-28C>$$[:F1O-'%);C-U6C)4;75*9V5M-"](-#5V8FU534-R0493
M2T5(;U)M=&1U*TDO=T%W4$LP=FQF>F9Q5VI/<$5-17!A,%IT*U9V2CA55"8C
M>$$[5C<O05)8,W)N4S1C;DA!4V52,4=%-#5M4&0Y>C9-+S5X,3$Y3E,O3#)+
M=TQ!,T=K5%-7-W)8-'94:UEZ4G-F8C1Y;R\Q8S%(845+>28C>$$[6#-U.3=,
M>6-72W8U<"]A.5%Z0F1I.&HO04]C;'1F4W@X:G=A4W)5;C%E-55&4$=',W!+
M-2MI5# O=GI99&Y1=60Y>G$K,6-L67A(*R8C>$$[8V9U+T%E1F9L6C55:SAZ
M*V5.33 W,"MD<$A)3&TO,G%O=#131V-.+W(W2C@R>EHV:DQW44ID4'!-4&E:
M0DAP,3EZ-U)Z;DAR2%EQ;"8C>$$[9FUP8E)V3$=R<F4P*W%'>750<D)05# O
M4V)L*T=767(T>%AE,5IQ-$I8>6]V:'EX<S=I.79B97IT:TUL>&-Y2D1#9S9S
M.&I"5D$K6B8C>$$[3V1+5%%S=DE!16UH>F9:+S5J95).4#A!3VYL=5A3-V=I
M2S51*W)96%AE2V-!9T4P-G$Q84U01#-!>FYD4&Y/3U9V5C9R5$1,0VIZ-B8C
M>$$[4&QE>6LX,2]L:C4S9VYU8EIO3"MX97)W<U0V9'A!,5992W<R6DA8;W<V
M2#-'8G=I3V%(:UAN26UE;GEB.'<K;&1*+T\W.'1T43 Q8B8C>$$[,3E8:G-N
M-#AP8E,U1$I-:E5Q5C1G2&XO04Q#=6%A5VEY03%6=2]H,FAI:TQU;FAN-7DO
M;6HO:FY63&)3.493539.85 O;S9L5#9L>B8C>$$[8TXX4'%C0G93:#1O3W4U
M<C%O3FYP3DXT47,O55A4-C=6*TY)0U P:C=4*T]4,'(X:79Y:75F3'DO=T-*
M3F9H.5!76FM+,E9O,4,Q=B8C>$$[131O>E T4T].<69S<G-D>5%-4%<V;U,Y
M3654;CEN84EW.6-X-G5N:SEK>EA/,EE"*V98+T%*2V989CA!;S$O-FI)8WET
M1B]E:C0O8R8C>$$[-%AA4#EX3#1F945R+W=#8V)V.$%Y5S0O-6I:+S%*;&YA
M2#DU.$=R<W8K-BM++SA!-7E*.'4O<%@X=G!,-DY!,7AO.'E84VUN>&5K,R8C
M>$$[-W%64C=58TUF.5A(45I/2$I896YT4$9X67(O;7-L+TMZ>31F3#-K3%(Y
M3V1/1GHV06YU9U)2=E=N4'%U1SDQ-6-F;WEN5EI/4$E3-28C>$$[1VIX8T=+
M239V3B\K8W%0*T]2;T@O35)0+W=!45A-=G,S;DIW3S$O<&HX5TPO=T1/3#,O
M2V(V;"\R>D@O04]O:4A,*S!F-W-E+W=$428C>$$[6$8W2B]V:B]!1E0Y-&94
M96%6-DHU+SA!;D8K5V$K9&1"5G)4:6UU869Y97=D:GA%9V%N3T9I9'%0>$A%
M;F]F66Y-=E-A:G<U8B]36"8C>$$[0C$R:SA73S,Q1&LK8W9*4&UN5R]Y-3@U
M+U=,;3%K4C1Q,C)Q869)3T1T17A"23,V34-!>6XK0GIB-7-58W-+*U1O<T=A
M5T1*6DAV1"8C>$$[-EHP-S@U9GDQ=G)*8G!D8V=T=W=Q,$9W5$9+<#=Q55EB
M:V8U3E(T6G!P85!)1%9045$Q,D=1=FE3-U-F>G,X=38Y-3,P+WEZ;T-0928C
M>$$[4EA);6$T,49W,%5A:4M&-4%S84U!-U9+-VMG1'=R:S5A3U591U5U;E)Q
M:C)H1V5546IV9E@T5SE&>D1D9RM14'HT9$@O3F984VI"9R8C>$$[1&)!:T=U
M-C)K24DK9VEM8B]29C-1+TA6-69T2"LK;#A0=40S6"]N2&HO>5=&;"]Z15A0
M+T%#9$]A,U@O04XT-VYS>BLU2'A41#@V=B8C>$$[2VXK22]W078W*TM.958U
M<#0K=C)L3W!A045U=G9Y:4QG1'AP:TY(;#1-9S=J<WDQ*TAJ>$AV1S<U8CAH
M*V%P+TMV;7I4.6)I-4=/,R8C>$$[:T%U;S$V=D$O=T%-<6(W5DMK,#DV2$XS
M;7AI8U1&-3-4-6IJ;4I$;RLR8E<V=#=U,6AU<F%14S(Y=VEY=WER=7))-$1+
M=SEI1&Y.:R8C>$$[14=I.61'44ES8VDX."]/9CAR0C4P,'!,=E1G<6593$)3
M3%5T4E)01515=T]X-F(W;U1S1#AY4FPV4%4K1V%0,&QW3F9O+T9&>"MS9B8C
M>$$[8C5F<65$+VQT-3,Q5#AT+TXP>6%L87I*85-F-E!Q*VYS=D=50E166%97
M-&IM:$Y26'%#4C-R;3 Q1T5:;V)F0C R;#%%<T4Y>#=W*R8C>$$[:5@O3W(X
M<VPP-#,O04]N25=4:GE%0W$U;DHO;#E,:GIR.'AM<"]*-6)Q;F5N6#1A=FEF
M3TAN<GI8<F8U;"MD165W=$I:05%,8E-D3R8C>$$[46-N5TU%;7)5,C5-87-X
M-V5.0FTS=S1O-%EB;C-U:#%'85=F2G-024(Y1"]!2E%F;&I$-4HP5C)U4W-U
M=5@T5G(K6F0Q44PY;4=-+R8C>$$[>7)88SEZ-U5Z539V52M)9'9P1'9D1G!0
M0FIV.5(U<R]Z16,Q0V%N<2ML85AB;34Q2SAH<V]"6#DW8U-,1W4S=7A'4VI!
M>3)!=&A/8R8C>$$[66DU1VYZ.2MC=C4T5V5T5T5V;')Y=7I35U4Y1G8Y4DE+
M*W%O25!P46<P8FE4.7!I3BMN5$YT<$Y'66YI;'ID2G)U,$)-8T5/6%5P:"8C
M>$$[*U)N-4Y8,7)E=V5A+TUK1%<W=R]&<&5N4T-K;DUJ86565#EN:BMW<#-R
M=G115FAR9%=+-$DO1G,W4#!*0C0U+T%F<&4K6G%N9$UC."8C>$$[.68T1"]2
M2"]!1'58,5 X05(Y5#9F,7IJ>355,SE(+V1N3VXK*SDX=7=E2F9O=3-(,4AH
M8U W>7$X+S!00G11+S9&;BMU3C9(-E4Y2R8C>$$[=3,Q9C%F4S8Y=E@O04AN
M,S5T62]M82]H9$Y,.'!E,T8K4&4Y42],1"]L4UAR+SA!3VYF5G8P;GA&9E@Y
M5#8U.6XT=4@Q;C0O.6(P+R8C>$$[:'I",5!J,38K6#)F6BML,D=K+TPS*S=R
M:2LS-V8P4%1-=VY9=7A62B].,RM'9CA!1#$Q+VEF,'8P2%=,-C,V.693<C9Q
M96YY<"]X6B8C>$$[>'EZ1GAC6' K<'%Z8TA#95 V5D1Y5B]G-SE$3B]H3#!0
M,%0V,&QF<71F5#E88FY3=C!D3G-L;30K3#$X,%E01#1F4CE+8F%P*VIV,"8C
M>$$[6F0O<$PP+S!D-DUN,3,Q<65N-DA!*W!Z<G1X-%9R;&-,<U9Z8DHQ=VYI
M-6155&M75$5F4"]W1'ER875N9C0Q*W$P-5,O;R\V,WDT,28C>$$[;W9Q57!T
M+TQ8;&U29SA89F<K3&DV;G=B2&E6-5=H4$DO=T1Y<50Y3EA(*T1V<5 V52MR
M;C9X.50U9C-(3F$O-49/9DAP:W,S:F-0<B8C>$$[=6U/;CA$:2]D,7A6,#=M
M8S5I=5DW1E=$+VU4+T%-<6XY1U O04)X.50U.&8S4'%C=G)80W8W2&]F-E)X
M<C1B6FQA9GAF-$PO045F<28C>$$[8U!6*T(O;$LO5#EM-WA9+SE#,2]79CA!
M<&(K;GDO>75&2R\X2%0X8S)8*T56+T,V;B]"3"]I97IF;&PO>7%8,$@O=U Y
M53E8:697-"8C>$$[."]R;D=O*S,V+S<O04E6.&9H>E<V;GAV-#<O43=84V5"
M6#=U=C O8G5Z=DU6>EAM,G8X02]+:68X43,O04]N9C!B*VUU82]8=G)83"8C
M>$$[;'HT:6XR=FAR>' Y;DTR2&HX231B-%A!>69L=4TX5F-85S)6*U-0.$DO
M-&9H+W=N-E@V1C5Y96PV2$QH>C5(;CEV-'9T6FHU=5!I.28C>$$[9DYY9%!W
M8U!O*VQ0<W%B;FMG+S9&<SE&+W=$:FHX9FDU5G)Z-S%P6#1V;%0V33)(*T4K
M8G)0.$%"2R]H96ME5V8P2"MG8DPY0F-F,"8C>$$[4#99*V\X3V9(,'$W8V5F
M>%4X37<X=D9X2&DU=69I-&5%8U P<&YL8EEW8CAY=CA!;%4S;U(O-#4K<#@V
M1#!E9E V,WAR*W@V2"MK8R8C>$$[82M',EI7;CAB*T,O,&9B<S17<CA$+TM6
M*VXW3C-J2V8Y0S O5SDO,'0V6$DO834K;%0V4#-L4'AZ62\T4E@X3'$O.$%"
M3"]I93$O;"8C>$$[=B]Y<7HV<DHO9V8V;C O9BML>2MT8V%I;G$K="]P2$=V
M5&QT;70Q2&DO>#,K:CE4=&1,-$9F=38O5"MT;6U9>FU/>%8U.2MD=BM"4"8C
M>$$[.$I*+VDO,2]Q+S%I4#9N.5,T9E<O5C<K;#9N=S T5C4X='%F-5A(3792
M*TIX*VHW951G9&]E2#1F<G9N=%A.2B]W07)0*U9&*W9&+R8C>$$[:&HP4#!Z
M='@K=CA!3#8U>3,O=2]8*TAL5'(V3U<V;G@V.5@P*UA,.&4Y<C!N-6$O4CE8
M;GHK,SE$,6Y.93=.+R\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @
M(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C1".3=#.4-#-S1%-T4U,3$Y.#4P1C<P.3(U1#!&,T9#/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.C1".3=#.4-#-S1%-T4U,3$Y.#4P1C<P.3(U1#!&,T9#/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO
M;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/G5U:60Z-&4V,F5A
M,CDM-69F-BTT9C<Q+3DX8V4M8C8T8S<P83(Q-S8Y/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C0U
M.3=#.4-#-S1%-T4U,3$Y.#4P1C<P.3(U1#!&,T9#/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO
M;D-L87-S/G!R;V]F.G!D9CPO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I!-41!-D$X
M-39#13=%-3$Q.3DV,3A"1D1%.4)$1D9",#PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q-BTP,RTQ,50Q-3HP
M-#HU."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-$(Y-T,Y0T,W-$4W134Q,3DX-3!&
M-S Y,C5$,$8S1D,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,38M,#,M,3%4,38Z,C0Z,3$K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @
M(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&
M86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S
M/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I
M>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$
M:6TZ=SXX+C4P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^
M,30N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y)
M;F-H97,\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53
M:7IE/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B
M92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MV\MV]W;SV]QXYXY/UU4&U/ZFS9L]O9ZB>:?LY[NSRR-)V]W [NWNXYX'/'/
M^FN0UZ-?#333333333333333333333333333333333333333333333333333
M3333333333333333333333333333333333333333333333333333337C.?\
M<%B+:_BJS9HS?<H^D8_JC<BC^4>@JNZ>O7 BG'PD'%M2*R$Y/RRX>GC(>-;N
M'CI3N,"94$5UDLCBL3D,W>AQV,KO9MSDA$7@*JCW>65VX2**,>[R.0JC[\D
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M[=-=]*2LBZ418Q$-%M7DM+R"[>/C6;IXNDB?VX['7<M<@Q^.K26K=ANR*&(
MDGCEF8DA4C106DD=ECC0%G95!.L?E<MCL'0L93*VX:-"HG?/8F)"J"0JJJ@%
MY))&(2**-7EED94C1G8 UYVW7$W/;OLFS&+.E[LG<923@SD&1R?FR1<1M9CV
M2ZJJ+>4L4-"SE7A*>P=^G<.(<L[E'YW.(I*HM:^E(-UF(2TW3/";?I1WM[;D
M%$R\]E+&H'F=@ 2D4DD4\EAEY D\5+QQD@F4J0VH+7K#N+=.1EQO3K:+9(0\
M>3(Y>0QUT1B0LD\,4U>&JC=K&+S9'S3 $+ '4IJP7@A_FB3Q#0GNXF I-8S8
MK!(ER-#8XEG\U1T+"BJLBLXKCV423D",)!!-"1^7.5'YX==TM$EEYM-D27?1
M/E$QJ9"TN(ELSXT2GT<ER-8[)B(! F5"4[D)*=ZA?(%#^.,L8UG#"OEI,72?
M.P4ZV7,(%^*A*\U,3@D%J[R .$D 63QL7,18Q>68()7H[?$0[S)O.F[UUMR@
M)A;\I]LA$(12,;+F"/G,MR\<W?72PO$R&*5PZKC=XTHC CI,YXEQ$V91B<B<
M^\\UF>D>W8L7M]<Q+&/7YKF7O8?/%0C=EK1*3]%F*M:8KQY!)"'Y,2\4]Z[;
MLFS.Z&P$$S?IFW@L)C5CXYLI+&KVYW X[FKJZTT# F)HK!0@3/S;%Z3VU6#V
MC[&,'T1M$H,+I<*I$Y5RJ]\!$Y&2R#?XQE.2+:25*4HKFJD<O&4IB;@"A'5Q
MJ;M%51956!]^9V7/[GR=HN6K5YY*-%>242I4=HD9!]O.X>R_].9OL !9GIGM
MN';&S</26();M58LEDGXX>2]>C2:19#]3Z9#'43Z?LX%]N22?==[.V2K[P=K
MV8, 69DS<*76HR1:C(NTR&-6L@QC=20HMG:K&#R-U8>RMX]=R*)TA>1AI"+7
M.+-^Z34Q>V\U/M_-X_*P,P%:PGJ$4GB:HY"6H&'W$D)<#D'M?L<#N12,SN_;
MM;=6W<I@[**3<K/Z:1@.:]Z,&2G84_53%85"W!'?'WQM\CL#11Z)6[^S[/-]
ME,I$_(/(S&>>+%'82RI77JAT6;*?E)-2)HEF<H*&!!I)U&ZO&[1W(+%Y9UJ8
MM+83$!T*B=G^I6WX-P[7LV8D5[N+A?)49E'+-$B"2U"I'NR6*REE4?O31P'W
M[>#3/I#NFQM7>=2G/(\>.S,Z8C)5W)")/+(8J=AE/RI)5MLJO(1\M>6RO([N
M1L5]5$U?#6M/ZSQ!#J>[O> $0"^01S" ?I V/Z;[C_<'<8"\C^X@'W$-7*Z<
M_P#L3M__ +++_P";LZY^=6O\(NZ?^VP?^1J:N!= /<*;.G3IQY7I.0%]:< 3
M]@PG,^943.?D\*=M8:&8$C")R,6='LD%762@<I*'KSI-,0.@JFG7WJKB?TO=
M]N5%[8,K%%DH^![>27NAM>_W9K,,LS#ZCRCGZ@FT_1+._K.PZ,$C]]G"3SXB
M;N/+>*'MGI'@^X1:=B&!#]"8& _=(&3O5<W&'VN[ ]QF3(Z0&.MC^EK8ZH:R
M*OB?)W+)BZ5+BY&-'D.Y[6T)A[;"@(B (0"Z@E4 GC/A=B8@9O=6'I.G? MD
M7+0/[IKT@;+H_P#1F,:P?UR@<CZC8>IF>.W-D9[(1OX[,E0T*1!X<6\@14C>
M/^G LKV?\F!CP>.-:[G9:B*V\C:8W, AY]S&!D^!]N2K91J@ /O^QBF 0'["
M @/VU;C<AXV[GC^,+E#_ )J,^J*;17G=FV%/\[<.%'^EDJW_ -];5?5&==)M
M4&_B'MZ$YG;=V\VXU^86_*7;)XH-2,;+F"/GLNRD<@[NMA>I$,4KAU6T7C>A
MQZ;I,YXEQ$V95BH1*P/ 5M1TDVY%B]OKF)8QZ_-<R][#YXL>CE:T*G[+,5-I
MRI'D$D(<$PKQ2GKKNV;,[H; 02M^F;>XA,:L?'-E)$5[<[@<!FKAEI(&!,31
M6"A F?FW'TO]J\!M"V38/QBPB&\=;9>H0^0LJ/2H%3?2^3;O%LIJS'D5P*51
MV,"99M48I18"G3@J]%H"0@I"&H"WMG)=P;ER=UY"\$=B2I17GE8Z55VC@[![
MA?+PUB0#V,LTAYX.K/\ 3K;<&UMH8?')$J69*L5[).  \N1N1I-8,C  MX>5
MJQ$^X@@B7[:S^4335*!54R*% Z:@%4*4Y0414*LBH & 0 Z2I"*IF_410A3E
M$#% 0U0$CZ'CZCV_!'!']H)!_(]M;L0#]0#[@^_O[@\@_P!8(!'X(YU_O37]
MUK=MAZ0-^LMAQ  X!'>'84@#CC@$[79" '' <<=O'' <?W!JX>Z#STZR!_.W
MH3_G@AU0798[>K&*7\;JL#_-9L#5TCK)X.J><NG-N8:V2,:.I+&./YG---E5
M44SOJ_9<7LE[0=Y&+G*)FRTK ,INLOC$X%:)G'[?V%4IBURZ=Y.QC-WX5H79
M4NVX\;8C!/;-#>80=K@?O!)6CF7GZ21(WVU;7JOAZV9V%N%;$:-)CJ,N7J2D
M O!8QJ&R6C)_=,L"35WX^L4SK]]5F_AC\K62M[R\J8D1>.#4[)V#I:>E(HJA
MO3?BK'MGKBM<F3I\B3R,X:RVZ, 0*!C!,%Y/PD!33/UIHPS;=HWRH]12R<<2
M2<?-X+<$PFCY_#20UW^_\G_'5>_AXR=BONO)8L.WI,CAY9Y(N?E]31L5S!+Q
M].5AL6H_R?*/QJWOODW+Q^S_ &G9OW$O4FKMYCNF.7%7C7@CZ67O4ZZ:UJB1
M+HI#D6,R?V^8AD)(4!%9&-,\<$#^"/%?]LX9]P9[&8A2RK;L 3NO[T=6)6FM
M2+[$=R5XY"G/L7[0?KJTF\=P1[6VSF,ZX5GH5&:M&_/;+=F9:]*)N"#V26I8
M5DX]PA8CZ:HM]'G!C_?MU,(*SYM<.<AL:NO;-R^775A 'YKC+0LO'FB4IOS%
M,U=M9;)%FK"\M&+(G9R$(C)1GI@:*&!.SO4')IM79DL&-5:C3K!A<>L7R"O'
M)&_>8^/F5HZ<,PC<'N24H_/=]:;=*L,^]>H4-G+EKR5FL[ARC3\/ZJ6*5/$)
M>X%762_8KM)&05>%9(^WM/ML4M5%U>[5,WXGC:K!UFYX2W?5:)0CW.1Q?XDR
MHX:H$02D[-7(PLSCV;=BF7^9F)"K-K+!O'2Q@4^54^ ;D[RMS"2Q713.2S5L
MEM^>0N*?9?HJQ)*0S/X[<:\_NQI.8954>WDL2D_753_B(VU#7MX?=-:)4:_W
MXO),HX$EB"/S49FX'S2O66Q"S'W\=6%??MU+)T!=YLWNHV9!1K],+3>3]M,R
MPQI,2;YP9S*SE!>QQGV,9V47.(J*NR1K.8IYW"PG<O\ \%_,WB[AZ^<*FT/J
MKMV+![C]55C$=+,QM=C10%2*TK]MV)   %[VCL<#V7U/8H"JHU)G1+=DVY-I
M^CO2F;([?F3'RR.2TDU)XR^.FD8^Y<1I+4)/+/Z3R.6=V.H=_B?MP]ME<Y81
MVNLI)TUH%/QNVS#-Q:*QTFDW>+C/VFLQCB20 >QT>L5RL*A#*G#^6&VSA2@(
MK"(2%T4Q%>/&9+-LBM;L7&Q\3D M'5KQ03.$/U7SS3#R#^=Z>(_;45_$5G;,
MF8P^W$D9:56@,K-&"0LURU-8KQ-(OT8UX*[>(G]WU4W'UU8DZ/N$Z!A/IV[8
M6U%C6#=SDK%]4S%=YALDD#ZPW;)4(QLTNZEW9"@H\<0R3UI567F,8641 Q\>
M3M3:E#41]0<E;R6[LV;3L13O3X^M&2>R&M3E:&-8U^BB0JT[<?O22NQ^NIVZ
M68BEB-B;=6G&BMD,;6RMR50.^>YD(4L2M*P]V:(.M9>?W(H$C'LNI,M:7J0M
M:IJT3:^X?=I8+%,+*.E\X;B)27DES'$5%SY)R2N[='[^>>3C,GX$!]O;MX
MU>F"(8C PPQ@*,9B$C0?8"G3"K^/^;US5L3'.[GGGE)9LQGI)9#[DGU^0+-]
M??\ Y4\:VL*222"2:"*9$D44R))))E B:2290(FFF0H 4A"% "E*4  I0
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M)%BQD$OLDS,.V9?F"GW (,W>HUU+^M<3LD4_ZUN,5 #]>]*X^P_L"MQM1?\
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MYP@9VK$_\Y X^H.MC]@'+$-G?!^(LT5]=%>(RECBG7MIX# 8K<;+ L95RP4
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M<1U)9&HW&)X5*]Q?%Y'/V2"8Q6'^ORQ'@<ZE#JAMR3=&RLQCJT9DO0QID:"
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M$9"\D2;,WCNOI?7?;6\-JYNQB8)I7HVZ5?SM5\C&2:&O/W"A>JO(S3($N1O
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ME6%VIOC86^TOX_;F=R-'$Y2>N;%3'V9HLEB)'>&1HWC3QR-/2?R(.2L5D(2
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M1\\#/T^MMBM22MGMD[GBW%'&(WK5:!2I9G4=O>#9:.W565_<Q"K;,7/:KR\
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MS*\\\TAY>261B[NQ_+,2?8 #Z  <#5KZ=2MCZM:C2@CK5*D,=>M!$.V.&&%
MD<:#\*H ]R2?J222==9S3EFN8(Q1?LQV^.LTI5<;UJ0MMC9TZ#<62Q_)(E,%
MY-U'PK8Z:KP&#,%7[T?*DDU8-G3QPJF@W5.7[8VA-E+]7'5W@CGN3)!"UB40
MP^20\(KR$$+WMPB^Q+.RJ 21KSY?)U\+C+N5M)8DK4*[V;"U86L3^&,<R,D*
M\%^Q>7?W 5%9R0%)U51W699Z@?7#/"X,VO;<;U@;9I\_CIJQ90S4@O365_5C
M7!7$5+VB4!)RT?0< X%&08X^QP-^?GFDV,],/W'I(LD'.F"H;3Z9^3)YO,5<
MIN+Q/%%1QI%AJG>.'CACY#I+*.4:W<](@C[HHT!9_+6S<N3WQUA,6&VY@;F%
MVGYXY;&1RX:HMXQMW1RV9.&5X86XD2C0]:YF"32R-VQB&P?T\]A&+^GK@9GB
M&A.E;+99AZ2R90R._9)L96^W [5-J=V#,BKGY178ELF$?6*ZF[=)Q3'S+N73
M^:DIB5D8FW;NJ[NW*-D+2B&&-?#1IHQ:.K7#%NWN('DFD8]\\Q52[< *D:1Q
MI..QME8[8V%3%4F-BQ*_J,C?= DMVT5"E^T%O%!$H\=> ,PC3EF9Y9)99/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g158779g96s57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g158779g96s57.jpg
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M 0$! 0$! 0$!_\  $0@ 00#( P$1  (1 0,1 ?_$ !X   (" P$! 0$
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M - IPW_\X=7_ /UM0_\ YOGY_P#*-U%_N_9?^)._^]?H_P FO3G^\5[_ .%
M_P#C7B1\!GAT(\\VO;^K9S%#+)C&5M0^6<Z:;;8QGY+?G\LYQ_/Y>63](S42
ME)3Y@LOI* _.3NLX_P!M55_1LTXE*E#4-[R$DC+4'J!/^QKU^ I_H/[C_P 5
ME?\ \07>1]([^<.GOU,[_CG:GZ-7\W=1?KIG_ M5?%YYTKTE1XI1XI1XI1XI
M1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI56/Q+O43KWM4
M3ZZR\JCK4FO,;E8GEG_<3O*?.H+.2H;"Y Q@,O[N;Y)3?J1_XK]'RB_I9^I_
M1Z_T4ZVLFCD:H3>#+!N]OC1HGDL</_:-":%;W[1&PG[=O!]+/'APX\<Z6M#W
MS6:]*FS"(19[C)DS/*I&XPTZ813NL-KVU?8.9'#'#CQJT[SD%=CK%._L1G_E
M2/\ TM_+M_G&_P"^G_F%4<_-N?W%?\IJB?X"G^@_N/\ Q65__$%WGHCZ1W\X
M=/?J9W_'.UYP^C5_-W47ZZ9_P+57Q>>=*])4>*4MWL?WI[Z\TYMT67E3F]T:
MN@AF6)M7[(A 8J,%L<+L[R)&V823!())P=YB@)2)(]"MY)!8QQ""-;) /#.#
MX54DCJR.W-<7ZN>US+VG39N-9X]8:M0(V[!'-:K':*[MO(Q7 Z%3Q+D8&9V1
ML6DY 0<I6^!!=9)Y?I3$;ADPZ%) Z^/A1*B>KAXTXOE:M1XI1XI1XI1XI1XI
M1XI1XI5;*OXA3BX]&ZOSSEGJ5WSJ.>0]"M?-[):JUFFB521Y5'1B<K4=T]?*
MP-9"OM,'P+Y2=6.@)(T\XT>DNFVW5'NC)F#:[-=+QK33=H%\MD.ZQ(<OR]<T
M1YK#;Z"J/'C/.$(V]VIT)+1<0M*5DI..3L]*$B?=;U:[-HC4MX\Q72;:9<V)
MY W",F%(<CK")$F2RWE>[WJ6BK>I;6A2T *!/!Y^*5G'<,>MV?4WN/\ &[;'
MSQS_ /-\Q_)YQ^TLWO\ MO[M_#?]DL9=?YR_L^/I?VK_ !'F2_)!_F_]:OKG
MI[ZO_P!I[B[[G]-\W?F_(=_^F_R?\UZW'U/2K&?ED_SB^J?U)U%]8O[,\HL^
M^_0?.7YSR[R?]!_E'Y[U?1]?T:[UM\0ES3.A\IY_U/U)[YR_'7>A53F]=M=D
MS3#*I"\MCH-.+@ERA?M =I!<%[,)E\1&S*4$4J88676'?.N-9Z,F)]LO-RL^
MM--W?S);)EUE0XOE[<U4>$PM]90Q)C,N;*]@-)=*=REQ:$K6"H5DG^E"1;[I
M9;9>=$:FL_GRZ0K3%FR_('(29$V0VPC;D1I+S>4;9=4T%%Y3:%J0A02<62^<
MKKK-'BE'BE'BE>)$N\ \\T8\Q<D,,LL8@^8-2"MX]-M]1X-BIQA<33;8Q'%D
MDD>#&^VN9IXH_P!4FMD@*4E)4E 4H K5M%* 3@J4$)6LI3S.RE2L#T4J. :J
M)2E2@E2RE)(0G9"ED#(2DK4A 4H\!MK2G)])21DBO3G?OJ7?_<=CZBF\+MW.
M7*"LMK$]<7BR5:=M#]LI5.5(XB6EF6Q 0*U7.!#=&(]V+Q%%OK#L)@CZNL'3
M+GT<HMNAFM;-ZAA71B3+9BQV+?$F)9)6\\P\I;\]N%)2MEUA:"TNWHVCZ07L
M[)5R^U])2[GKQW0[FG)UJD1H;\N2_<9<-3P"&67V$MQ[>Y-C+0^T^AP.IN"]
MD>B4;>T$]][<^Q?9>"M.-A<GX#8NWB]!L393<#$*ZU'Z4-> 168A&C#:M(74
M8\)L;EE+INTW!@VPHFS'+OKH1F+&Z*TQ8M1LWQR]:DBZ?7;(K+\%$EV&V;DZ
MXF6I;#7E<F.5*06&@0R'%#?)RD93G)ZWU5?M-O6%NR:9E:A1=);S$YR,U-<%
MM:;7$2AYWR2-("4N!]U0+Q;3]@K!.%;,E^U'7+[P[BMDZ1S/ES;L=P3G5X9?
M04H[DIBUA;/0%9Y$,*!6Y:;:K BIV,N8%\NFL8VVTVT46-Y-<5H^RVW4%^BV
MJ[7=FQ07VY2W;E(4PAIE3,=QYM*E27F&07G$):3M.I)*QL@JP#EM9WRY:=T_
M+NUHL[U^G1W(J&K9'1(6Z^E^2TRZI*8S+[Q#+:U.JV6E !!*B$Y(J7F^*/[N
M30RPY^&_TW7$L4D>=L(.MY_3^O3.OS^7\-\?/Y?/Y_+SLZ>B'H_2I*ORJ6@[
M)!_2;+U'/]JUQ)73'TA*2I/Y*+N-H$?HU\ZQC^R:D+X)/-^B<UXWV5=T6A72
M@L&/35IJ\&ZU9Y53#@]*L!!N6&*]! G*&UGTWAVG@TWBUEUVCSOC?7.,8WI^
MNMKNU]L3MKN4"Y--6EUMURWS(\QMMPS'5!#BX[CB4+*2%!*B#@@XQ64^CU:;
MK:;#?VKK;+A;'7;NTXTW<(<F$XXV(322MM$EMM2T!0*2I((!&,YJZ[S@=>@J
M/%*4'WZ_N<^P'^XLW_,UOED>L/;[C55^J?9[Q4#_  D/[G:7_?Z\_P#OA?)7
MS]GQ-0CE[?@*8W?V?@M=UMM!X9SRP=H:\_,_&7NQ+7-?JG/:T\_I_KK.]N?E
MXRZLD&8]L&+:XI;PKL_T&)HDNN\>D8ZR0/?]W\/=4[74!GW??6MYQ[ATNU]6
M,X)?ZK:>+=K&AP4%2KSE20#:1,PR$ZETJUHF#!)8X=QHIIHM=9 R2<#F:ACD
M[KS\"BG SD$=H_?0*!..1[*Q?9CW6YMZO$IEMQK'17#.PEZ )Y5-6*"K$Y>V
M@<TNF]R?;*T!&H8YP\IVJ0EV4'G;>&<72>$B.$$E7+'SX4*@.>?NJ.NN?$(K
M/,1\VI9Q+M%_Y"&= $S[37ZY$%SZ3$Y.@>I=9:-YA=;(LW,WU"$>?J65UJ9M
M%$F<L8YX)I 1W@'LZ_;V5!7W$CMIRJOU&B6_FJKKJ>P@XYZVK&+A%8SY=5P8
M:'4/<TLMIL7F/"W*R*(C1K$7F/=?.,3"3C3>"3&(P<XZ^56SD9ZJ66R^W%P&
MIA75Z'ZS].OW'@UL[_-XP\IM89.*N-%L3+:ZQ0&S22YLT,H.F6 $K%6C/8 9
MU8#K\@;QE[SLCD5<>6,$_CRJ-HXR!D=N?A4X<*[_ ,V]B>;A]0YRUEGK\LI(
M305K%$ WK38"**=@GL N)YX0C@X)QR=]XBB0IPR!C@RR R(9]X((.#4@@C-1
MK6/9I]TJLL^C<AXQ9>A<N .=AJ[-'9JX@>7N*N'%+6S'GM39[YW;K\, 30EV
MUA;U,IH2++&,)_.+,D[..!.#[O$]7XU&UGB!D>_P'7^%;KU%CH)G%0+CSD"Q
M H>H77J'4R?W<,M$M)#N^=&L[UMN[@4RSA1S!D$84@PZ$E2C)ERP0@HDB"6>
M3*WJ\2[U*8D2]A)BVVUVMAMO:W;46UP&(+(0%J407 R7W<'9+[SJDA*5!(Q-
MDLT2R19$:)MJ$NYW6ZR'7-C>NRKM<)$]]2RA* 0VI\,-9&T&&6DJ4I22HTR[
M_P"L%P_^'G_Z5R^>C!_1H/C_ .>BO-A_I/#P_P#7QJ]OM'.*KTNFC 6[+*(&
MH7"C=37FI )6CH!URVV*;TOW5@# LS3)CMD<B8H)<"2S/6,SP%T?WA4.V/.M
MBNDRTSENPMT7)L&XVAUN0XEJ.Y'O$)^W.AYQ;C3:$MB0'T..N):;=:;<=.PA
M5>D;_:H5V@(;G;X-P9UNO+3D=M3TAN19IK%R:++:&WG'%.&,6%MM-K>=:><:
M:&\6FDZ7?$^X"YZW>N0J:WUPE[0*JV=GPE<]<*;'8K(%8*U75O/*9SMMH'T%
MQ<G1ECCW'7LJXCU%'$G,+WC71&'!;R[T2:D8LMNO;TJRIC7*8S':4BYL/18L
M5R-*E.W.?<V2NV,0&&XI"G6I4@K4M+: 75-MN:&STOZ9D7RXV)B)?%2;9"?D
MNI<M<AB5*E-R8D5JUP+4\$71^?(<E@I:=B1@A"%..$-)<<;S.,?$GXSU#F?=
MNHVRMWCC27UZ: ++Z%?UT&K..=Q,:&G7AAKIB")+(6U7S)9ZUO#H<&VG &VW
MEU,TDTI?NBJ_6B[:=M$*5;[](U,RX];7+8ZHLE+"6W'W5N.I0D14,N)D)EA1
M:6REQ8QL$'Z6#I9L%XM&I+S-B7&PQ]+/-LW-NYLI#P4\7$,-(;:4I1EK>;5'
M5$*0XA]3:"3O 1LG_NO=*[Q0+V9-]9[?)P@Q(GN.S,:_4PCI8E ?8$G5W(GG
MD6=U?V1"\\)G*N@ODS0$(CZS 430<S8;XQM P9-_<TFWJN"-1(D/P-TNW3TV
ME=RC%:7H*;F0'MXEUMQE+JK<EEQQ&RVM96@*^TGI GQ=/MZN<TE..FUQF)Y>
M3<H"KNBV20VIF>NU@EG84TZV\II-R4\VVK:<0@)7L.5SCHE2ZO0JITNC--&]
M/NB(&PHF7T]Q]I5YT.)==21YL:S!F"[_ %!3PY]=)PC()Q9]=)8=]<:-=+9-
MLURFVFX,EB= D.19#60K9=;5LG84G*5H6,+;6DE+B%)6DE*@:WRU72#>K9"N
M]N>#\&X1FY49W!25-.IV@%I5A3;B#E#K:@%-N)4A0"DD4M"3VX-ZFWM,'K?Q
MRR=OJ=)<%5U]TO2U52AT!G8@,:Y8(J&VL94AMV+7YVQ&6R"6!U;67>'Z5CFB
M(AFWVJ1HMNSLPU:IOD73\RX,(E1K48<RXW)J*X3NI-Q9BH#=O0Z!M(:<=7,*
M0K,5)2I(U*/K9R\OS$Z4L4K4,*WOKB2;N)L*W6QZ6UC>QK:]*67+@MK.%O-L
MHA E.S+4%))JXX+T ;IOQJ.AVJ"O6>HD;\K*3MJM<5\"VR5]Y7>?4E$Z5,H0
MS&*Z?(S%>1@5DI9,5#4+89DK/+!*@GWZ]J.VKM/0+;(:I42:GSTA]B9!=4[%
MDQY5QN$AAYI3B&G4[;3B=MI]II]EP+:>:;<0I(XYIJYHN_T@+I-3%EP5FR+C
MOPI[26I<63%MEOCR&'4MK=:7L.M*V'F'76'VRAYEUQM:5&R'V1^(5R'UKMM8
MH%CJ?57EON#V&OHHQ:&\KM5**RQ7KC21KI<!421^ LW9A['%4O>UZC[$C138
MBVGUSKRW2O1G>]5PIERB3+/'A08ZI,DKN4>3,0@-.NMI7 @JDR(SCH:6&T3Q
M#*@A:DY">/5]6=*%CTG.AVR7"O,B=/DIBQ@BVR8L-:RZTTXM%PG(C1I+;)=;
M+B[>9NSMH! *N$I^TGMA0?4RD27OH%:Z0_4Z[019WH].,<!#$&D?9KX6MC-F
M5U5+L:;G0:&)B\@+DWDC^D)+F:#67#Z0T;<M9W 6VVR[7&?.T<7"<AA:TMIW
MCA9BMI>F/[ML%:BU'4@ ':6G"L9G6.M;9HFW&Y7.)=I+ V!FW0%OMI4XO=MI
M>E.*9AQRXX0E(>D)621LH5M)!7%Y\2)7/RU!T[DWKSVCMR^>EH[G>YZ&JC(J
MG-<-$0C]C67=TV@E!<VNM!EZ_N-560&L:+,4VCXI05'N+KM$?HL=3>)-HO6I
M[#I]U,^1 MR;B\I,RZEF2N,U+8@Y2Y'A2UMGR5Z6XR9&4F,A]!"ZU63TKLJL
MT:\632VH-0M*M\>X7%5M8"H5I#T9N2[$D3RE3<B;$;<_E3$-M\1L$25L*&S3
M3^K_ +,\Y]LN4+NL\UV90+)F!J)VC=PP0.ZS9%L8TQZ1K&(06)M-J*< Q$(%
M*F@+6L 2?G%)+(/#J&KM)W31EY=LMV#2GDM-R&)$=2E1Y<5TK2W(9*TH6$E;
M;C2TK0E2'6G$<0D*5N6C]76K6UE9O=I+J65.N1I$>0E*9$26R$*=CO!"UHV@
MAQMU"D+4E;+K:^!44IXEC[8PV'I-_P"2\%YH^[G<.3ZB1=-.66*L4VD5!R?D
MO 52(M=E-URTMTN0#=9U:52>&KD%)&<M5Q@Q T7[VM&JC6JVWK4=UC:>@WDK
M-I;=BRYUPG,-[&\FHA16_LH2=XV4O/O-+>"T+89=0M*U8]W6J95VN=DTW:9.
MHIUDV$W=QF5$@6Z#(<V]W!5-EN#?3E%MP*9CLNMLJ0M$AYE:5)$'TKXH_$K)
M8K'SZP<W[]4>L4HIB#<^;0\K=WYVC(4&Q+6)'U><8M,<ZF Z<<>-K/&# 1L2
M+O%IF(H;>;8)_1#J"+%BW.+=--SK+/0TY!NJKS&ML>0EYM3K2<74PREY3:5J
M+*2XI.PL$Y0L)UVW],6GI<J7:Y-IU-"O=O6ZW/M";+)N<F,IAQ+3J\VKRQ*F
M$N*2E+Z@VE>V@@;*T%4W^_7]SGV _P!Q9O\ F:WSE:/6'M]QKK"_5/L]XI'O
M2&TNJ-\+GJEQKDDL#^LIN\/$I4/SQ($S7)BB F&GR_G_ -7DQZ&Y^7R_D/G'
MZM?Z\65ZX]GO-53P0?;[A4Q_"-PLSZA!2A8TR?/T>\RV"7'\Y9V^9EVL<I._
M^5O/E+JGT_5OG.V8M(OY_+Y>0OUO94HY>VH!^,6NDJ<GK=VZM2?B[U4KFT5+
MVXV/TF[?:86VM!G>37Y2;Z)FJHV<33&V,:;MC/Z_K?RE'6/X?)J%CD?9^SXU
MM_C)[[%<AX--./\ 1D(Z;OO,/)C&=H=IJP3O*/OC./Y_HVSG3?&<8QG.O\\>
M&^OV?&B^KV_"GZ]UA!=?4'V!$U&@U%'Y19?MQM(M-8(,!K\R"8ABUUQ''@;>
M&+:#&FNN(LQZ9TQK^G'RJGUA\]565ZI^>NJA[3<'==^"WRT5:21%BX7)O3VT
MT4F^LOX3^,72G,HWU=<XVT'(VKH:^;3&<:2B32"28VAFWTVO_7/</@!5/Z@[
MS\2:M<J_).R-:;7=T'M@XWJC*LJ-THT7&>/[@[UXQ4/E=!'I^#S'L+LMDACT
MU_GIM#G&/YZY\J2,^KQS_K&K $CUN&.P<JT7JWZ0UGU@JW4Z6LZ!9[DAZH,#
M">(V#7K-D^PRYTI.*5[ ;;X^X9AMX(B))=,_3RK!SI\_EMC,%6<''*I"<9&>
M=5TTWJWLQ\+TS7EW6:&3U3UAT?,-JC>J[#]&=2*X8S';Y6,OU;@+CS"22F!M
M'M>0Y9VTALB-_A=ML<7; 7Q' _//]O\ "J@E' \1\\OV5<=Z^WKDO1N6(K9Q
M(R FA-2WAHH\6"82%3AFY.<V%4Q -DD)5GC.61F\JW;.!1HIH/Q>-E&Z_?>A
MSGCSJXQCARJC7?\ U@N'_P //_TKE\]1#^C0?'_ST5Y5/])X>'_KXU]&GGER
MO5=4.^O:Q<9\;OVN)+!%((3\I-9JIIH8Y)%S&=9PU5,<'OMKG(Y4JQLS DFC
MSK)N*>7#MMG2>3&WHO4SKJ/H_P"C4H<6E+]Y0T\E*B ZTE[4+R6W #Z2 ZRT
MX$G("VT*QE((\W:89:<^D-K52VT+4Q9%O,J4D$M.J9TXRIQLGU5EIYYLJ&#L
M.+3R415IWM33_7>P<(Z&#[)?B4_'9M5[ZZLYSC4$FAJMBO(4'1,$>T+@EWLR
M$7!KA0L%,&\VT":$0[!6 IN/:/G:GC:BMCFE=\_?$[V- :2VW)&P\TZAYLM2
M IA$<-..K=6YL-,IVGU+;V-L=EUG TM*TW=&]6;ABPJ#4FX/*<<C$.,NM+8<
M2['*7UR"ZVTAI#>VZ^K982AS;W:D<[K;;9=/A\]1_@_S1?R3UR2>O[%;2"NE
M[M&%_MO/$U:C!2[UVCKV46:HI:)QAI$-JNUN:6 L22%F?0]XR(9RN@Z=A0X'
M29://EU<O6J']2M.STVK<MVV'<WY9<D>57!QI0F/,OK6),.WPF8R%@LMW$%*
MDHYUJ2=-N'1A>38K2U8]*Q],.LV]5VWSESFVN/$#3'DMN:=3Y$P\PE!C3;A.
M>E+;(>=MI"TE4"T_HEBYK\"&.UULL@5WM2;-4QSH)-]" @KS[#N:"Q(@GTSB
M0:89-8#/LR(MM9!Y]8-X=X]]--]=CFVR+=OI$F%+0A<<7&+-4VH H<7;M,L7
M)I"DG@M*WXJ-M*@0M)4% @D'6H-UE6CZ-XFQ%J1(-NEPDN))2MMNXZH?MCJT
M*'%*D,2E["@0I*@DI((!%BWPX%251Z/>MXR**&(0CGP[4KZ&-<:R.G+-DUL$
MLF=?\J;=V8PS-G;Y[8D_5KG_ "?ECF'2F](?Z0=5*DE16FYK91M9X1V&FF8P
M&?ZHCH:V>HCCUUU3HH9CL='>DT1@D(5:T/+V<8,A]YUZ23CFHR%N[6>.<YI
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M)^'9[<Z^RN.J8Y+EE,BXO,MNK7%8CQFHP?"'7Y+K:%17>AH7J76+2(MST_\
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M?QJ1G@3_ *H'[S\FF<\BK4>*4>*4>*4>*4>*4>*4>*4J'3?[W7JI_N![-_\
MMN.>6'JJ]GOJI]9/M]U-?Y6K4>*4>*4>*4>*4>*4>*4>*4>*4>*4>*4>*4>*
M4>*4L/NI_=+]B/\ A+<O^43^2.8\1[Z@\CX'W4R2[_-X/_DQO_1T\B@Y#P'N
+K,\5-'BE'BE?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
